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ABSTRACT 
Sarcopenia provides the underlying basis for loss of physical function and 
disability in older adults. In addition to sarcopenia’s direct effect on limiting mobility and 
movement, significant loss of muscle mass is associated the onset of type 2 diabetes, 
osteoporosis, obesity, and arthritis, as well as increased mortality.  The prevalence of 
disability and co-morbidities in our growing aged population has the potential to add 
hundreds of billions of dollars to annual health care costs. In response to this impending 
health and financial burden, the scientific community has made a concerted effort to 
gain a better understanding of this condition with the goal of improved prevention and 
treatment strategies. 
The cause of age-related muscle loss is multifactorial and includes denervation, 
impairments in vascular function, and declining levels of circulating hormones and 
growth factors that repair tissue and promote growth. The complex etiology of 
sarcopenia warrants a multisystem approach in the development of therapeutic 
strategies to prevent and/or treat age-related disabilities.  
Our lab has defined a role for the α7β1 integrin, a transmembrane adhesion 
protein, in the protection of skeletal muscle from damage associated with mechanical 
force during exercise. Transgenic expression of the α7B integrin isoform in mouse 
muscle (α7Tg) additionally enhances new fiber formation, myofiber hypertrophy, and 
vessel growth following single or repeated bouts of eccentric exercise.  One of the 
unique phenotypes of α7Tg mice is the accumulation of a stem cell population that we 
have isolated and characterized as a heterogeneous population of mesenchymal-like 
stem cells (MSCs). The ability for MSCs to significantly increase muscle and vessel 
growth post-exercise suggested that they provided the cellular basis for beneficial 
adaptations observed in α7Tg mice.  Collectively, these studies demonstrated the 
potential for the α7 integrin and mMSCs in the prevention and/or treatment of age-
related disabilities. 
The purpose of the first study was to develop a MSC-based therapy for the 
treatment of sarcopenia in mice.  Preliminary experiments demonstrated that MSCs 
were dysfunctional in the aged microenvironment post-transplantation and did not 
effectively reverse age-related decrements in muscle mass and function.  Thus, a 
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preconditioning method was developed to promote survival and function in aged 
skeletal muscle post-transplantation. Our lab recently demonstrated that MSCs derived 
from skeletal muscle (mMSCs) are highly sensitive to mechanical strain and secrete 
numerous growth and neurotrophic factors that can impact MSC survival and local and 
distal tissue health. Thus, mMSCs isolated from young animals were mechanically 
strained and immediately injected into the hind limbs of 24 month old mice. In addition 
to measuring indices of muscle health, the impact of transplantation on distal tissues, 
including the brain, was also assessed.  We hypothesized that mMSC paracrine factor 
release would allow for beneficial adaptations in both muscle and brain tissue. 
Transplantation stabilized the neuromuscular junction and increased muscle function, 
as well as increased neurogenesis in the hippocampus. Thus, these data suggest that 
mMSC preconditioning prior to transplantation may provide a novel method to prevent 
or reverse age-related impairments in muscle strength, neuroplasticity, and cognitive 
function. 
In a separate study we investigated the extent to which overexpression of the α7
integrin could preserve muscle mass and function with progression of age. α7Tg mice 
from our colonies were reserved for this purpose and muscle tissue was collected at 
6mo, 16mo, and 24mo either in the sedentary state or following injury created by an 
acute bout of eccentric exercise. Skeletal muscles were analyzed for α7 integrin protein 
expression, markers of muscle damage, and mMSC quantitation. While α7 integrin 
protein declined in both α7Tg and wild type littermates, integrin expression was higher in 
α7Tg mice throughout the lifespan.  The attrition rate was lower for α7Tg mice, perhaps 
due to improvements in maintenance of muscle mass, protection from sarcolemmal 
damage, and preservation of the mMSC response to injury.   
In conclusion, the studies presented in this dissertation provide evidence that both 
MSCs and the α7 integrin provide therapeutic targets for the prevention and treatment of 
age-related disabilities.  Development of methods or approaches that can enhance α7 
integrin protein or optimize endogenous MSC function in humans may provide a realistic 
and effective means increasing quality of life throughout the lifespan.     
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CHAPTER 1 
INTRODUCTION 
 Skeletal muscle is a complex, highly structured tissue that requires the 
coordination of multiple factors and many systems to properly function. The endocrine 
system guides its development and growth through the regulated release of hormones 
and growth factors. The immune system helps repair it. The nervous system controls its 
every move through a complex network of signaling pathways initiating in the brain. The 
cardiovascular system supplies it with the fuel it needs to perform. While there are 
hundreds of myopathies that intrinsically impact skeletal muscle structure and health, 
disruption to any one of these systems can be equally detrimental to skeletal muscle 
health and function (6). 
 Sarcopenia, ambiguously defined as the loss of skeletal muscle mass and 
function, occurs after development as a natural process of aging. Since the aging 
process affects nearly every system of the body, potential mechanisms underlying 
sarcopenia include a wide variety of factors, including decreased endocrine function and 
sensitivity, chronic inflammation, denervation, and compromised vascularization  (13, 
26, 33). A number of promising treatments are currently under investigation (e.g. 
various exercise interventions, nutritional, androgen, and pharmacological therapies), 
and the development of a multifactorial, multisystem anti-sarcopenic treatment is 
desired (13). 
 
1.1 Significance 
 From 2000 to 2010 the number of individuals in the United States aged 65 years 
or older has increased 15%, and in the next 20 years that number is projected to 
increase to over 72 million individuals (1). Of this elderly population, recent estimates 
indicate that approximately 45% are affected by sarcopenia, which equates to 18 million 
individuals today (19). If prevalence rates persist, due to the paucity of prevention 
strategies, proper identification and effective treatments, this number will rise to over 32 
million sarcopenic Americans in 2030. These projections are not likely to decline as 
sarcopenia has yet to be recognized by the Centers for Medicare and Medicaid 
Services or the Food and Drug Administration as a treatable geriatric condition (13).  
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 Sarcopenia represents a major cause of disability and increased health care 
costs in older persons (18). Using data from the U.S. census, Third National Health and 
Nutrition Examination (NHANES) Survey, and National Medicare and Utilization 
Expenditure Survey, Jenssen et al. (19) estimated that sarcopenia alone results in an 
excess cost of $18.4 billion a year to the health care system. Though sarcopenia 
contributes to numerous other health problems, and accounts for a similar percentage 
of healthcare costs as osteoporosis, public health campaigns directly aimed at reducing 
the prevalence do not currently exist (19). 
 In addition to sarcopenia’s direct effect on health and function, the loss muscle 
has been associated with increased risk of accidental falls and disability (19, 32), type 2 
diabetes, osteoporosis, obesity, and arthritis (11, 15), as well as increased mortality 
(25).  This increased risk of disability and co-morbidities has the potential to add 
hundreds of billions of dollars to annual health care costs. This impending financial 
burden has stimulated a major effort in the scientific community to gain a better 
understanding of this condition with the goal of improved prevention and treatment 
strategies. Since 1994, the number of sarcopenia-related publications posted on 
PubMed has increased from 4 to 345 in 2012. Although significant gains in knowledge 
have occurred over the last 20 years, it is clear that more progress is necessary. What 
we do know is that age-related muscle loss is inevitable and prevalence rates have not 
improved. That said, development of future therapies and interventions to halt or 
reverse the effects of sarcopenia are a realistic goal and research in this area of study 
should be a priority within the scientific community.   
 
1.2 Specific Aims 
Specific Aim 1: We will determine whether a newly developed preconditioning 
method will increase muscle-derived mesenchymal stem cell (mMSC) survival 
and function following transplantation into an aged microenvironment.  
 In our previous work in young healthy tissue we have clearly demonstrated a role 
for mMSCs in skeletal muscle growth (38, 40). For this reason we would like to target 
this same cell population for therapeutic applications in diseased and aged populations. 
A common barrier to all stem cell based therapeutics is low transplantation efficiency 
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and dysregulation by diseased microenvironments (5, 31). To overcome these barriers, 
several groups are developing various preconditioning methods including chemical, 
physical, and genetic manipulations (31). Based on our preliminary data we 
hypothesized that subjecting mMSCs to a single application of mechanical strain for 5 
hours at 10% on a laminin substrate will physically “prime” these cells for increased 
survival and the ability to secrete factors important for skeletal muscle health. Proteomic 
array and in vivo data support this hypothesis. Not only have we been able to 
demonstrate increased release of paracrine factors following strain on laminin (17), but 
preliminary data suggest enhanced cell viability in transplanted aged tissue.  
 Other groups have implemented similar strategies and have reported promising 
results. In these studies muscle derived stem cells were mechanically strained prior to 
transplantation into infarted hearts (5, 28). Preconditioned muscle derived stem cells 
improved angiogenesis, vasomotor and cardiac function, and increased release of 
vascular endothelial growth factor (VEGF) by the cells appeared to provide the basis for 
these observations.  Several other groups are developing unique preconditioning 
strategies to improve MSC-mediated enhancements in tissue health and function, and 
many of these therapies are in the clinical trial phase (31).  
 To further test this hypothesis we will isolate mMSCs from young healthy mice as 
previously described, and mechanically strain them for 5 hours on a LM substrate (38). 
Immediately following this preconditioning technique cells will be lifted and re-seeded 
onto polydimethylsiloxane (PDMS) elastomer gels that mimic the aged 
microenvironment (i.e. high collagen content and stiff physical properties). These 
cultures will be followed for 7 days, and cell survival and growth factor release will be 
assessed compared to non-preconditioned controls. Cell survival will be measured by 
counting the number of cells in five-10X images captured daily. Cells will be collected on 
the 7th day and qRT-PCR will be used to quantify growth factor gene expression.  
 To confirm cell survival in our in vivo experiments transplanted cells will be sex 
mismatched and fluorescence in situ hybridization (FISH) analysis identifying the Y 
chromosome will be performed. 
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Specific Aim 2: We will determine whether preconditioned mMCSs can increase 
muscle mass and improve muscle function in aged mice. 
 Based on data obtained in our lab, mMSCs have the potential to indirectly 
contribute to muscle growth through the release of paracrine factors (22, 38, 39). 
Several of these factors including insulin-like growth hormone (IGF-1), IGF-1 binding 
proteins (IGFBP) (7), leukemia inhibitory (LIF), and hepatocyte growth factor (HGF) 
have been shown to have trophic effects on muscle. Combined with their potential to 
release immune-modulatory, anti-apoptotic, and anti-fibrotic factors (10), mMSCs have 
the potential to positively affect the muscle microenvironment and increase satellite cell 
activation, myofiber size, and myofiber growth.  Specifically we are interested in the 
local release of IGF-1 and IGFBPs from mMSCs. IGF-1 has been shown to stimulate 
satellite cells (16) and block the age-related loss of muscle function (3). As both of these 
variables decrease with age, an increase in IGF-1 and its bioactivity could enhance 
preservation and/or growth of muscle tissue and could have a significant impact on 
muscle function. 
 To test this hypothesis, mMSCs isolated from young healthy mice will be 
preconditioned as previously described then transplanted into the gastrocnemius/soleus 
complex of 24 month old C57BL6 mice through intramuscular injections. Seven days 
following transplantation, recipient mice will be sacrificed and transplanted muscle will 
be collected. Analyzed primarily through immunohistological techniques satellite cell 
percentage, and myofiber cross-sectional areas will be assessed in addition to wet 
muscle mass. To determine the impact that these measures have on muscle function, 
grip strength dynamometry analysis will be performed pre, 1wk, and 4wks post stem cell 
injection. For this test a series of 3 maximal grips will be measured and peak force will 
be analyzed. 
  
Specific Aim 3: We will determine whether preconditioned mMSCs can preserve 
the neuromuscular junction in aged skeletal muscle. If so, we will determine if 
this has implications for central nervous system health and cognitive function as 
a result of the well established interdependence of the two systems. 
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 The natural process of aging has been shown to detrimentally affect most, if not 
all, systems in the body. Due to the well-established neural component of the 
sarcopenic phenotype (4), we would like to explore the potential for mMSCs to reverse 
age-related neuromuscular degeneration through increased junction stabilization (23, 
29). Since muscle function is largely dependent on the proper structure and formation of 
neuromuscular junctions (6), preservation of this connection is crucial to the 
maintenance of muscle mass and function. 
 Contrary to traditional theories, the nervous system, both peripheral and central, 
is highly plastic (4, 23). Strongly influenced by neurotrophic factors produced both 
locally and from surrounding tissues, the nervous system has the ability to adapt to 
varying challenges and its ever-changing environment (8, 9, 24). Within the secretory 
profile of MSCs, several factors have been shown to have neurotrophic effects (30). The 
factors that we are most interested in are IGF-1 and epidermal growth factor (EGF). The 
focus of many studies, IGF-1 has proven to be a powerful mediator in neural plasticity 
acting as a reparative, protective and trophic factor (11, 23, 27, 29). EGF, a factor that is 
upregulated in mMSCs in response to mechanical strain to levels 4-fold higher than 
non-strained controls, has both neuroprotective and potent neuroproliferative effects 
(35, 36). Produced primarily outside of the nervous system, both factors can circulate 
within the vascular system and have the capacity to travel within the central nervous 
system through axonal retrograde transport (2, 20). 
To test this hypothesis a combination of histological and functional assessments 
will be preformed. To assess local morphological adaptations, the transplanted skeletal 
muscle tissue will be costained with α-bungarotoxin and synaptophysin to compare 
stable innervation percentages between treatment groups. To test the impact of 
improved neuromuscular junction stability, isometric force tests involving maximal 
exogenous stimulation of the sciatic nerve will be performed. Additionally, the brains will 
be paraformaldehyde perfused and stained for doublecortin to assess neurotrophic 
mediated increases in immature neurons. To test the impact of central nervous system 
adaptation on cognitive function a battery of cognitive tests including the rotarod, 
contextual fear conditioning, and water maze tests will be performed. 
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Specific Aim 4: We will determine whether transplantation of preconditioned 
mMSCs into aged skeletal muscle can increase vascular growth and function.   
 Our lab has recently established a role for mMSCs in vessel growth within 
skeletal muscle tissue (17). Similar to the rationale in the previous aim, age-related 
declines in cardiovascular system structure and function have the potential to impact 
muscle function, as well as the progression of the sarcopenic phenotype (26). With 
decreased vasomotor responsiveness and flow, hormonal and nutrient supply to muscle 
tissue is impaired (21). Found primarily in the vascular niche (17, 38), mMSC paracrine 
factor release has the potential to greatly impact the cardiovascular system.  
 Studies suggest that IGF-1 is an important protective factor in the cardiovascular 
system (37). Not only has IGF-1 been shown to have anti-inflammatory effects through 
the attenuation of mitochondrial oxidative stress, but it has also proven to be an 
important mediator of endothelial progenitor cell survival and growth (14, 37). As the 
cardiovascular system exhibits particular susceptibility to age-related functional decline, 
protection of this system through anti-inflammatory and regenerative mechanisms could 
have a substantial impact on muscle function.  
To test whether paracrine factors released from mMSCs positively impact 
vascular tissue growth and function within the skeletal muscle, a cohort of mice will be 
longitudinally tested for changes in hind limb blood flow using SPECT-CT imaging 
technology. Using the radioisotope tracer 99mTC-tetrofosmin, in vivo hind limb flow rates 
will be measured pre, 1wk, and 4wks post transplantation. Combining these functional 
measures with a thorough CD31+ vessel (endothelial cell) histological assessment we 
will be able to determine whether adaptive or maladaptive remodeling occurred as a 
result of treatment. 
 
Specific Aim 5: We will determine whether α7 integrin overexpression can 
preserve skeletal muscle mass over the lifespan 
Our lab has observed that overexpression of α7BX2 integrin in young healthy 
animals (MCK:α7BX2; α7Tg) results in protection from damage, enhanced satellite cell 
activation, and accelerated myogenesis in response to an acute bout of eccentric 
exercise (22).  We have also demonstrated that mMSCs are increased in skeletal 
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muscle following an acute bout of eccentric exercise (38). Although we don’t fully 
understand the mechanisms which underlie the accumulation of mMSCs post-exercise, 
mMSC number and mMSC response to exercise appear to be α7 integrin dependent as 
they are minimally present in α7 integrin knockout mice in the sedentary state and 
increased in α7Tg mice in the sedentary state and post exercise (38). The degree to 
which α7 integrin expression and mMSCs accumulation in muscle is affected by age has 
not been thoroughly investigated. 
 In this study, α7Tg and wild type (WT) littermates will be aged in house, and body 
weight and grip strengths will be collected at regular intervals. Three cohorts of animals 
will be aged to 6 months, 16 months, and 24 months. Animals will be euthanized at 
these respective ages and tissues will be collected and analyzed for α7 protein, collagen 
content, IgG+ damaged myofibers, and mMSC content. These data will be compared 
between age groups and genotypes. We hypothesize that overexpression of the α7 
integrin across the lifespan will confer protection from damage and preserve the repair 
process which are known mechanisms underlining the age-related loss of muscle mass 
and function (34), thereby strengthening the α7 integrin as realistic therapeutic target. 
 
1.3 Summary 
The long-term goal of these studies is to develop novel therapies utilizing 
preconditioned muscle-derived stem cells and/or the α7 integrin for the treatment of 
sarcopenia. This approach will target multiple systems as the etiology of this condition 
has proven to be highly complex. 
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 Sarcopenia 
Definition 
Although first observed in 1931 by Macdonald Critchley, a young neurologist at 
King’s College Hospital in London, as “the entire musculature tend[s] with advancing 
age to undergo involutional changes, which are manifested as wasting (29),” it wasn’t 
until the 1970’s that Nathan Shock performed the first large-scale longitudinal study 
reporting that “no decline in structure and function is more dramatic than the decline in 
muscle mass that develops as we age.”(60) Fast-forward almost twenty years and this 
well-established medical phenomenon remained unclassified. Recognizing that in order 
for a condition to stimulate scientific and clinical interest, a name was required, in 1989 
Dr. Irwin Rosenberg proposed the term sarcopenia, from the Greek “sarx” meaning 
flesh and “penia” meaning loss (114). Adopting the term, Evans and Campbell were the 
first to define sarcopenia as an age-related decline in muscle mass (48). Although 
naming and defining this condition proved to be an important first step, this broad and 
non-operationalized definition lead to ambiguity in the treatment, diagnosis, and 
understanding of prevalence of this condition. 
Since 1993 there have been several attempts to construct a more strict definition. 
In 1998 Baumgartner et al. (8) put forth the first quantitative measure of muscle loss 
using the skeletal mass index (SMI). Similar to the body mass index (BMI), SMI is 
defined as appendicular lean mass (ALM), the muscle mass of the four limbs as 
measured by dual-energy x-ray absorptiometry (DEXA), divided by height squared, or 
SMI=ALM/h2. For the purpose of the study, Baumgartner classified a person sarcopenic 
if they were two standard deviations lower than a young healthy reference group that 
was measured in an earlier study. Although this definition gained traction, several 
groups attempted to fine-tune it over the next eleven years by creating more appropriate 
cut points, developing prediction equations based on less costly assessments, and 
accounting for an individual’s fat mass. Unfortunately, instead of bringing more clarity to 
the issue, more confusion and ambiguity were created as few were consistently 
classified as sarcopenic under the ever-changing definition. 
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To add to the complexity several groups have argued the importance of including 
loss of function to the definition. While it is clear loss of lean mass has functional 
impairment outcomes, which functional parameters (i.e. power, strength, or endurance) 
and which tests (e.g. gait speed, hand grip, or 400 meter walk test) most tightly 
correlate with muscle loss have been debated for several years (130).   
Despite the confusion and inconsistency of reported prevalence rates, medical 
and scientific interest has grown as the personal and financial impact of sarcopenia is 
undoubtedly great. Recognizing the need for an accepted clinical definition and 
diagnostic criteria an international group of leading geriatricians and scientists from both 
academia and industry met in Rome in 2009 for the International Sarcopenia 
Consensus Conference Working Group Meeting (53). The following consensus 
definition was formulated: 
Sarcopenia is the age-associated loss of skeletal muscle mass and 
function. Sarcopenia is a complex syndrome that is associated with 
muscle mass alone or in conjunction with increased fat mass. The causes 
of sarcopenia are multi-factorial and can include disuse, changing 
endocrine function, chronic diseases, inflammation, insulin resistance, and 
nutritional deficiencies. While cachexia may be a component of 
sarcopenia, the two conditions are not the same. 
In addition criteria for evaluation and clinical diagnosis were determined and include 
objective SMI cut points of < 7.23 kg/m2 for men and < 5.67 kg/m2 for women, and a 
functional measure of gait speed < 1.0 m/sec over the course of a 4 meter walk. This 
particular test of function was chosen for its established predictive value for the onset of 
disability (59).  Although professional organizations such as Centers for Medicare and 
Medicaid Services and the Food and Drug Administration have yet to recognize 
sarcopenia as a treatable geriatric condition, having a precise definition and specific 
diagnostic criteria is movement in the right direction (53). 
 
Onset and Progression 
 Muscle mass and size peaks in the mid-20’s and is relatively well maintained 
through the 5th decade of life 83). For many reasons, not all of which are well 
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understood, a disruption in tissue maintenance occurs around 50 with accelerated loss 
beyond 60 years of age (39). Measured through the 8th decade of life, several studies 
have established that after 50 years of age muscle mass is reduced approximately 1% 
each year (39, 60). Though this rate varies, and appears to be higher in sedentary 
individuals and males, muscle loss with increasing age is a phenomenon that affects all 
humans (94). Whether or not this loss results in an individual dropping below the 
clinically defined sarcopenic cut point is highly contingent on baseline levels of muscle 
mass and age at the time of measurement. For these reasons sarcopenia appears to be 
a greater public health concern for females who have overall less muscle mass at 
baseline, and who tend to live longer (112). 
 
Pathogenesis 
Decreased Physical Activity and Nutritional Status 
 While inactivity and inadequate energy consumption contribute to muscle loss at 
any age, studies suggest that both are predominant factors that contribute to the 
etiology of sarcopenia (43). According to a 2011 United States Department for Health 
and Human Services report (1) less than 18% of adults over the age of 65 years meet 
the physical activity guidelines that were established in 2008. This estimate declines to 
12.3% for individuals over the age of 75 years, a rate 2.5-fold less than individuals 
between the ages of 18 and 24 years. This same report highlights a substantial 
decrease in mean energy intake of 35% for males (2946 to 1941 kcal) and 26% for 
females (1973 to 1466 kcal) when comparing 20-39 year olds to adults over 75 years of 
age (1). Although these variables are correlated, both seem to independently contribute 
to the loss of muscle mass and function that occurs with age. 
 
Decreased Endocrine Function  
 Multiple changes in the production and efficacy of hormones are known to occur 
with age, and evidence linking these changes to the loss of muscle mass and function 
has been the focus of many studies. Probably the most thoroughly studied, due to its 
highly anabolic effects, is serum testosterone. While dehydroepiandrosterone (DHEA) 
and total testosterone are significantly decreased in men and women, a concomitant 
rise in sex hormone binding globulin (SHBG) exacerbates these changes. SHBG bound 
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testosterone represents the biologically inactive form of testosterone which is unable to 
confer an anabolic effect (11). Combined, these changes result in a 64% reduction in 
bioactive testosterone in men between the ages of 25 and 85 years (116). Although a 
less abundant anabolic hormone in women, a 28% decline in bioactive testosterone can 
occur over the same time span (74).   
  The hypertrophic effects of the growth hormone (GH)/insulin-like growth factor 1 
(IGF-1) axis are also well documented in younger persons. Starting around 30 years of 
age, levels of GH progressively decline at a rate of greater than 1% annually (134). 
Among its affects on numerous cell processes, GH has been shown to increase the 
transcriptional activity of several mitochondrial proteins improving the oxidative capacity 
of skeletal muscle (116). In the long term though, GH’s primary anabolic effects are 
through upregulation of IGF-1 synthesis in the liver. Therefore, due to their relationship, 
it is not surprising that decreased levels GH result in lower circulating IGF-1 (64). 
Further compounding this change, and similar to the changes in bioactive testosterone, 
it has also been established that the milieu of IGF-1 binding proteins, which strongly 
influence activity and clearance, are affected by age (116). The overall result of altered 
IGF-1 availability at the cellular level is decreased satellite cell differentiation as well as 
protein synthesis of existing fibers (112). Although the mechanisms are still unclear, 
there are also strong correlations between low IGF-1 levels and muscle strength, 
walking speed and mobility (16). 
 More recent evidence has established that a locally produced isoform of IGF-1, 
termed “mechanogrowth factor” (MGF) is also decreased with age (100). When 
compared to young, aged muscle had lower baseline levels of MGF mRNA and was 
less responsive to chronic loading. The consequence of this is decreased satellite cell 
proliferation, which contributes to lower capacity for muscle repair and growth (62, 100). 
The overall impact of satellite cell dysregulation is greater susceptibility to damage 
accumulation, and subsequent decrease in tissue regeneration.   
   In addition to loss of lean mass, aging is associated with a progressive increase 
in intra- and intermyocellular adipose accumulation. The result is an increase in the risk 
of insulin resistance (112). While it is accepted that insulin stimulates amino acid uptake 
and promotes protein synthesis while inhibiting protein degradation (117), its anabolic 
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effect on skeletal muscle remains controversial (112). Regardless of whether the effects 
are direct or indirect, the metabolic effects of insulin insensitivity on body composition 
changes that occur with age are undeniable.   
 While several endocrine factors are altered with increased age (e.g. estrogens, 
parathyroid hormone (PTH), cholecystokinin (CCK), leptin, etc.) and have been 
associated with various mechanisms contributing to sarcopenia (112, 116), an 
exhaustive review of all the possible hormonal factors that might play a role in the 
development of sarcopenia is not the purpose of this review. As such, the main and 
seemingly most important factors have been discussed (i.e. DHEA, testosterone, 
SHGB, GH/IGF-1, MGF, and insulin resistance). What is certain is that a hormonal 
component likely contributes to the interrelated and complex mechanisms that underlie 
the sarcopenic phenotype. 
       
Chronic Inflammation 
 In addition to the immune response associated with many age-related chronic 
medical conditions such as arthritis, obesity, heart disease and cancer, aging is 
independently associated with a gradual increase in the production of inflammatory 
cytokines (112). In particular, aged peripheral mononuclear blood cells have been 
shown to produce higher levels of interlukin-1 and -6 (IL-1 & IL-6) as well as tumor 
necrosis factor alpha (TNFα) (116, 112). While it is difficult to classify these factors, 
especially IL-6, as adaptive or maladaptive, driving dysfunction or reactionary, these 
cytokines clearly modulate the production of anabolic and catabolic hormones, and 
evidence exists directly linking them to protein degradation and/or apoptosis signaling 
pathways (39).  
Over time this change in the cytokine milieu also leads to a disruption in the 
highly synchronized inflammatory response critical for proper muscle regeneration (26). 
Despite its post-mitotic classification, skeletal muscle is in a continual state of 
adaptation and repair. With the disruption in inflammatory signals, elderly individuals 
have an increased susceptibility to muscle damage. The long-term result is an 
accumulation of damage and loss of proper function (116). 
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Protein Metabolism 
 All of the changes outlined in the previous sections lead to a decrease in 
anabolic stimuli with corresponding increases in catabolism. The result of these 
changes is a tipping of the balance in protein metabolism in favor of overall loss of 
protein (Figure 1A). In a study by Balagopal et al. (5) which compared individuals in 
their 20’s (young), 50’s (middle age), and mid 70’s (old), significant decreases in whole 
body, mixed muscle and myosin fraction synthesis rates were observed by age 50 
years, with continued decline into old age. This finding has been confirmed by multiple 
studies (44). The net result is muscle atrophy, with significant decreases in single fiber 
and whole muscle cross sectional area (CSA) (85). 
 Although each stimulus has a unique mechanism, ultimately the signaling 
pathways driving muscle protein synthesis or breakdown are affected. Collectively, 
anabolic stimuli (e.g. amino acid availability, anabolic hormones and growth factors, and 
exercise) activate the phosphatidyl inositol 3 kinase/serine-threonine kinase (PI3K)/ 
AKT system, while inhibiting protein loss by phosphorylating the forkhead protein 
FOXO, a transcription factor that increases ubiquitin proteasome-mediated protein 
degradation. In contrast, catabolic stimuli (e.g. amino acid deficiency, catabolic 
hormones and cytokines, and inactivity) inactivate the AKT pathway while at the same 
time driving FOXO, NF-κB and Caspase-8 pathways leading to protein degradation and 
cell apoptosis (71) (Figure 1B).           
Anabolic Stimuli: 
-Amino Acid Availability 
-Anabolic Hormones 
-IGF-1, MGF 
-Exercise
Catabolic Stimuli: 
-Amino Acid Deficiency 
-Catabolic Hormones 
-TNFα, IL-1, IL-6 
-Inactivity 
AKT
GSK38
mTOR
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eIF2B p70S6K 4E-BP1 MuRF1 Atrogin-1
43S pre-initiation  
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Ribosomal 
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mRNA binding to 
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Protein DegradationProtein Synthesis
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Figure 2.1. Protein Metabolism 
An illustration of the balance between 
protein anabolism and catabolism 
leading to either hypertrophy or 
atrophy. (A). Signaling pathways 
important in protein synthesis and 
degradation (B). 
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 One of the most important factors contributing to the age related loss in muscle 
mass is denervation (38). Due to the plasticity of both the nervous and muscular 
systems, denervation-reinnervation cycling is a normal physiological process in young 
healthy skeletal muscle (39). Unfortunately over time this process is impaired. 
Beginning with neuron apoptosis that begins at 60 years of age (78), a reduction in the 
total number of α-motor neurons has been measured to be as high as 50% by the 7th 
decade of life (43). This eventually results in a decreased number of fibers with 
functioning neuromuscular junctions. Although an attempt is made by the body to 
preserve these junctions through collateral re-innervation by surviving motor neurons, 
this compensatory response is unable keep up, and the result is increased size of the 
existing motor units, and more often fiber apoptosis (47). In probably the most thorough 
and convincing study, Lexell et al. (84) quantified muscle fibers number post mortem 
and found a 40% decline in the total number of fibers in the vastus lateralis when 
comparing 24 to 77 year olds. Considerable evidence also exists that larger motor 
neurons are more susceptible to loss resulting in a preferential loss of Type II muscle 
fibers. This neuromuscular remodeling drives not only increases in muscle atrophy, as 
reinnervation by smaller neurons leads to a more type I profile with smaller CSAs, but 
more significantly a reduction in the proportion of Type II fibers (119). 
   
Impact on Muscle Function 
 Muscle function can be described in terms of strength, power, or endurance, and 
each of these parameters are negatively affected by age. While the main effect of mass 
loss appears to be strength decrements, trying to tease out and describe sarcopenia’s 
contribution and mechanism for this loss is less than straight forward as few studies use 
the same methodology, and few come to the same conclusions (39, 112). Typically 
measured as maximal volitional contraction through handgrip or knee extension tests, 
strength decrements of 1.5% annually beyond the 5th decade of life, and as high as 
3.6% in the 7th decade have been observed (86, 57). Despite following a similar time 
course, the loss of strength appears to be more rapid and therefore cannot be fully 
accounted for by the loss of mass.  It has been estimated that sarcopenia only accounts 
for 90% of the age-related variability in strength (55). 
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 In an attempt to determine the factors driving this observed discrepancy a host of 
studies have investigated the effects of age on specific tension. Specific tension, also 
termed muscle quality, is a measure of force production relative to a given unit of 
muscle tissue, and it can be assessed at the single fiber or whole muscle level (39). 
Unfortunately, the data from these studies have produced conflicting results. While 
many authors have reported a decrease in specific tension with age (33, 86, 88), others 
have observed no change (73, 91, 99). In one of the more convincing studies where the 
same investigators measured specific tensions in both whole muscle and single fibers, a 
significant 30% decrease was observed only at the single fiber level (54). These 
findings provide evidence for a deficit in the contractile properties of muscle.   
 Other factors that have been investigated, and seem to contribute to age-related 
loss of strength, include pennation angle changes, the preferential loss of Type II fibers, 
excitation-contraction (EC) coupling protein disruption, decline in coordinated muscle 
action, and composition and stiffness changes of the force transmitting extracellular 
matrix and tendons (92). There does not appear to be any consensus as to the 
predominant factors that contribute to loss of muscle strength with age. 
 
 
2.2 Age-Associated Neuromuscular Degeneration 
 Deficits in the structure of the neuromuscular system are recognized as a major 
cause of age-related declines in muscle function.  In addition to the denervation of 
skeletal muscle described above, alterations to this complex signaling pathway that 
occur throughout the nervous system, as well as within pre- and post-synaptic 
machinery, have an impact on the development of the sarcopenic phenotype. Beginning 
at the central nervous system, loss of neurons and neuron function has been observed 
in both the brain and spinal cord (21). Moving down the pathway, Schwann cell 
apoptosis resulting in decreased axon myelination and increased internodal length (34) 
eventually lead to slower signal propagation. Finally, axonal atrophy and decreased pre-
synaptic sprouting, both of which increase with age, bring about diminished neural 
signal transmission (19, 89).  
 In order for the neural impulse to result in muscle contraction the signal must 
cross the synaptic cleft and be detected by the post-synaptic membrane also known as 
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the motor endplate (20).  Similar to the pre-synaptic remodeling described above, age-
related changes in the post-synaptic membrane result in decreased excitation-
contraction (EC) coupling. A significant decrease in post-synaptic membrane folding, 
which minimizes synapse area, and acetylcholine receptor dispersion are consistently 
observed in aged motor endplates (38). Lack of acetylcholine receptor activation at the 
motor endplate, and decreased depolarization within T-tubules can significantly 
decrease calcium release from the sarcoplasmic reticulum (SR). Lastly, dyhydropyridine 
receptor (DHPR) expression and stabilization of the junction between T-tubules and the 
SR is decreased with age (20). The end result is EC uncoupling and ultimately 
functional declines.   
 An important question that has yet to be answered is whether deleterious 
remodeling observed along the neuromuscular signaling pathway is driven by aging of 
nervous system, a result of age-related skeletal muscle deterioration, or whether these 
changes occur in parallel. Considerable evidence is building to support the idea that 
there is a strong relationship between the two systems, and that proper interaction is 
crucial to the survival and function of both tissue types (38). Studies suggest that 
neurotrophic factors may strongly regulate neurons and neuromuscular junction 
remodeling.  
 According to neurotrophic theory, locally derived factors are taken up by axons 
and transported back to the neuron cell body through retrograde axonal transport where 
they have the ability to influence function and survival (32, 75).  Although there are 
several known neurotrophic factors, IGF-1 appears to be vital to the survival of motor 
neurons (38). In addition to its hypertrophic effects within skeletal muscle, IGF-1 has 
been shown to reverse axon atrophy (89), increase neural sprouting (89), attenuate 
denervation (103), prevent EC uncoupling (132), and prevent the decline in fiber specific 
force (103). Due to the established age-related decline in IGF-1 described in the 
previous section, it seems reasonable to implicate this factor as an important mediator 
of the sarcopenic phenotype. 
 While it is clear that inactivity contributes to the loss of muscle mass experienced 
over the course of one’s life, activity-dependent mechanisms appear to be equally 
important in the health and survival of the nervous system.  Deschenes et al. (38) 
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recently examined the effects of muscle recruitment on the structure and stability of the 
peripheral nervous system. In agreement with previous literature, there was a high level 
of Type II fiber denervation in the plantaris muscle of aged rats. Surprisingly, there also 
appeared to be equal proportions of Type I fiber denervation in this same muscle. In 
contrast, in the highly-recruited, postural soleus muscle little to no neuromuscular 
junction remodeling or denervation was observed regardless of fiber type (76-79% Type 
I/21-24% Type II (41)). This study suggests that while Type II fibers with large motor 
neurons experience denervation there also seems to be activity/recruitment-dependent 
mechanisms involved.  
 Similarly, within the central nervous system activity-dependent mechanisms have 
been associated with hippocampal neurogenesis and neuroprotection (10, 110). In fact, 
over the last 15 years a large body of literature has accumulated establishing the role of 
activity-mediated growth factors in neural plasticity (i.e. neuron survival, improvement in 
neuronal function, and neurogenesis) (87). Although many factors have been evaluated, 
IGF-1, which is interestingly synthesized mostly outside of the brain, has shown 
significant promise (10, 87). Whether these central adaptations have a direct impact on 
the preservation of neuromuscular function have yet to be explored, but they do provide 
exciting evidence for future studies to explore the relationship between the nervous and 
skeletal muscle systems.  
 
Impact on Muscle Function 
 Significant declines in muscle power have been associated with age (39), and 
similar to strength, the loss of power is only partially accounted for by decreased muscle 
mass (52). Power, which can be defined as force development divided by time, is highly 
dependent on rapid neuromuscular activation. For this reason, in an attempt to elucidate 
the mechanisms responsible for this loss, as well as to account for the mass to power 
discrepancy several studies have investigated the neuromuscular system (39).   
 Using electromyography to analyze electrical transmission speeds of motor units, 
Vaillancourt et al. (127) consistently observed a shift towards slower firing rates (10Hz 
vs. 40Hz) during maximal voluntary contractions when comparing old vs. young 
subjects. This observation is in agreement with data suggesting age-related preferential 
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loss of the power generating fast-twitch motor units with concomitant axon 
demyelination, both adaptations that would result in slower transmission speeds.  
 As was described earlier, the electrical signal from the nervous system must 
result in calcium release from the SR in order for contraction to take place. Again, 
because of the time component of power, disruption to this process will result in 
decreases in muscle power. Interestingly, researchers have found that the amount of 
calcium released from the SR is attenuated in aged muscle (35). These data give 
functional significance to the decreased expression of EC coupling proteins, specifically 
DHPR, associated with age.  
 
2.3 Aging of the Peripheral Vasculature 
 An important component of muscle health and function is adequate vascular 
supply, and similar to the mechanisms that contribute to skeletal muscle loss (e.g. 
decreased physical activity, poor nutrition, decreased endocrine function, and chronic 
inflammation) vascular structure and function are susceptible to age-related decline. In 
addition to the primary responsibility of oxygen delivery, the cardiovascular system 
serves as a pipeline for hormone and growth factor transport. For these reasons, age-
related changes in the vasculature, particularly in the vessels that supply skeletal 
muscle, have the potential to contribute to the etiology of sarcopenia.  
   Structurally the cardiovascular system is a complex network of conduits ranging 
in size from large central vessels down to the microvessels in the periphery. Starting 
with the larger central vessels such as the aorta, age-related remodeling characterized 
by dilation causing increased wall tension, and increased stiffness is consistently 
observed (126). This remodeling results in a decrease in arterial compliance, the effects 
of which are passed on to the resistance vessels, the arterioles, through increased 
pulse pressure. Over time this causes a maladaptive hypertrophic response where the 
medial layer of arterioles is thickened and the lumen size is often reduced. Combined 
with a lower shear rate that is often observed in aged arteries, the end result is 
decreased flow through the microvasculature (23).  
 Another important hallmark of the aging cardiovascular system is microvessel 
rarefaction (126). As a direct result of increased inflammation and/or oxidative stress, 
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endothelial apoptosis increases concomitantly with impairment in angiogeneis.  With 
both pathologies increasing with age, these mechanisms are thought to drive the 
decreases in capillary densities observed in aged tissue (111, 126).  Ultimately, these 
age-related remodeling responses lead to decreased blood flow resulting in inadequate 
oxygen, nutrient, hormone, and growth factor supply to downstream tissue (126). 
 In addition to these structural changes, aging is also associated with diminished 
vasomotor responsiveness (76). With evidence to support lower sensitivity of arteriolar 
tone to various stimuli, as well as increased endothelial dysfunction, reduced flow may 
be a product of not only microvascular rarefaction, but concomitant vasodilatory 
dysfunction (126). This compromise of cardiovascular function has potentially 
devastating implications for skeletal muscle as it could increase hypoxia, free radical 
stress, and lead to inadequate nutrient delivery at rest (92).    
 
Impact on Muscle Function 
 Muscular endurance is defined as the capacity to resist muscular fatigue (39). In 
contrast to the overwhelming evidence for age-related decreases in strength and power, 
the literature evaluating endurance is equivocal. The primary reason for this is the 
variability in testing modality. While some investigators assess the drop in force 
production over a series of maximal muscle contractions, others utilize tests of duration 
and sustained submaximal contraction. While the purpose of this review is not to explain 
the highly complex mechanisms of fatigue, it is clear that poor vascular supply could 
contribute to muscle fatiguability. Whether it is through decreased oxygen availability, 
metabolite accumulation, or substrate depletion, decreased vascular densities and flow 
deficiencies will increase fatigue and inversely decrease muscular endurance. Also, of 
more practical significance, as it relates to sarcopenia and this study, decreased 
muscular endurance has been shown to impair balance and functional task 
performance (63) as well as contribute to the incidence of falls among the elderly (118).        
 
2.4 Therapeutic Strategies to Combat Sarcopenia  
 Over the last 20 years scientific interest in understanding the etiology, its impact 
on individual and population wide health, the financial burden, and therapeutic 
strategies to prevent and treat sarcopenia have increased exponentially. Although 
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knowledge has increased, development of effective treatments are warranted. 
Currently, the only available treatments include interventions to promote healthy eating 
and increased physical activity (53).  
 Due to the well documented changes in endocrine function, much attention has 
been given to hormone replacement therapies. Of all the hormones that have been 
investigated DHEA, estrogen, and GH have shown the least promise. As a precursor to 
both male and female sex hormones, DHEA replacement has been shown to increase 
the levels of testosterone and IGF-1 in women and men, respectively. Despite these 
consistently observed outcome measures, few studies have reported an effect on 
muscle size, strength or function (112). The effects of estrogen replacement therapies 
are equally equivocal. Although there is some epidemiological and interventional 
evidence to suggest estrogens prevent the loss of muscle mass in women due to 
estrogen’s inverse relationship with proinflammatory cytokines, the concomitant rise in 
SHBG and resulting decrease in free testosterone brings the effectiveness of this 
strategy into question (112). The least convincing data come from studies investigating 
the effectiveness of GH replacement therapy. While this strategy consistently results in 
an increase in muscle mass, increased strength and function are not observed 
outcomes. Additionally, GH replacement has been associated with several adverse 
effects including increased risk of cancer, arthralgia, diabetes, and carpal tunnel 
syndrome (69).  
 Although it’s clear that more work needs to be done, promising data has been 
reported in several studies investigating the potential of testosterone and local IGF-1 
replacement therapies. In particular, a tremendous amount of data has accrued 
supporting testosterone as an effective treatment for the improvement of muscle mass 
and function. In fact, despite the lack of large-scale, long-term studies, prescribed 
testosterone supplementation for hypo-gonadal men has increased substantially over 
the last several years (7). However, several unanswered questions regarding the risks 
of testosterone therapies remain. Some very serious side effects have been associated 
with this strategy (e.g. thrombotic complications, increased risk for prostate cancer, liver 
toxicity, severe heart failure, etc.), and must be addressed before large-scale 
implementation (7, 69). Although much less is known, local IGF-1 replacement has 
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shown similar promise. Primarily coming from animal studies, local IGF-1 
supplementation or genetic over-expression has resulted in increased satellite cell 
activity and muscle hypertrophy as well as improved strength (6, 62). While the 
investigation of IGF-1 supplementation is still in the preliminary stages, these results are 
continuing to drive research in this area.  
 Other strategies that have received some attention are myostatin and reactive 
oxygen species (ROS) production inhibition. The aim of these strategies is the 
regulation of protein metabolism that is clearly affected by age. While both strategies 
have shown promising results in the preservation of muscle mass, consistent 
improvements in muscle function, when measured, are lacking (37, 133). Despite this, 
both strategies have and are being tested in National Institutes of Health (NIH) funded 
human clinical trials (96).  
 As of today, there are 30 open clinical trials being conducted through the NIH. Of 
those, 22 include interventions. With some overlap in intervention strategy, the 
therapeutic targets currently under investigation include various nutritional supplements 
(e.g. specific amino acids, omega-3 fatty acids, vitamin D, and HMB), hormone 
replacement (e.g. insulin, testosterone), pharmacological agents (e.g. Allopurinoc- a 
xanthine oxidase inhibitor, Rapamycin, BYM338- a myostatin inhibitor), and various 
exercise programs (96). While the results of these studies may provide new and exciting 
treatment strategies, the complexity of the sarcopenic phenotype warrants further 
investigation with novel and multifaceted approaches.  
 
2.5 Adult Stem Cells 
 Over the last 50 years knowledge and understanding of the adult stem cell (e.g. 
various populations, potency, their role in tissue maintenance, and therapeutic potential) 
has grown significantly. Residing in practically every tissue in the body, these cells have 
the enormous responsibility of maintaining the health and viability of post-mitotic tissues 
(80). In young, healthy tissues these cells have the ability to respond to a multitude of 
physical and chemical cues, proliferate asymmetrically to self-renew and maintain the 
stem cell pool as well produce daughter cells to replace damaged tissue, and secrete 
numerous factors that have trophic and immune-modulatory effects (2). Unfortunately, 
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the total number, as well as the proliferative and regenerative potential of these cells, 
declines with age (45, 120). Though clearly related, the impact that these changes have 
on age-related pathologies remains unknown.  
 Specifically within skeletal muscle it is generally accepted that the traditional 
myogenic precursor, the satellite cell, experiences these same age-related declines in 
both number and function (12, 121, 123, 131). Whether these declines are due to 
intrinsic- and/or extrinsically regulated factors is still intensely debated, although 
considerable evidence is accumulating to support the later. Data from several studies 
now suggest the regenerative potential of satellite cells can be restored when local 
factors, circulating systemic factors and/or niche composition are modified to resemble 
that of young skeletal muscle  (6, 22, 26, 66).  
 More recently, a number of studies have identified non-satellite stem cell 
populations that play an important role in the maintenance of skeletal muscle health and 
function (98, 104). While it is more challenging to summarize this literature due to the 
lack of consensus on isolation and culture methods, introducing a high degree of 
population heterogeneity both within and between studies, a potential role for these 
cells in the age-related dysregulation of tissue maintenance exists. Identified as muscle 
derived stem cells (MDSCs), side population cells, mesangioblasts, pericytes, or 
mesenchymal stem cells (MSCs) (98), these cells seem to display similar age-related 
declines in proliferative and regenerative potential, perhaps as a result of environmental 
cues (120).  
 Unique among these non-satellite cell populations is the immune-privileged MSC 
population (31). While these cells have shown to possess the ability to directly 
contribute to the repair of multiple tissue types including muscle, nervous and vascular 
tissues, the primary responsibility of this population is to indirectly impact several 
different cellular processes through the release of a plethora of paracrine factors (2, 31, 
108). While an exhaustive list is beyond the scope of this review, MSCs have been 
shown to release factors directing growth and angiogenesis, as well as anti-apoptotic, 
anti-fibrotic, immune-modulating, and chemoattractant factors (31). For this reason 
MSCs are a particularly attractive therapeutic target for conditions where several factors 
and mechanisms are affected.  
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 Considering all of their potential benefits it is obvious why MSCs have been the 
focus of so many studies and therapeutic strategies. Unfortunately, stem cell based 
therapies have encountered many barriers including low transplantation efficiency, 
misguided homing, and dysregulation by diseased microenvironments (18, 108). In spite 
of these major barriers MSCs have demonstrated efficacy in the treatment of a wide 
range of pathologies (105), though it is likely that their full potential has not been 
realized. With this in mind, a currently favored strategy to improve the survival, homing 
and secretory profile of MSCs is various preconditioning methods (108).  Testing a 
variety of preconditioning modes (e.g. physiologic, genetic, protein/cytokine, 
pharmacological, cellular, or physical) several researchers have been able to show 
improved cellular profiles post transplantation (108). This is an exciting and promising 
area of research with potential applications in many fields. To date, no stem cell based 
therapies exist for the age-related loss of skeletal muscle mass and function. 
 
2.6 The α7β1 Integrin, Protection from Damage and Regeneration 
The α7β1 integrin, a heterodimeric transmembrane protein linking the actin 
cytoskeleton the extracellular matrix, is highly expressed in skeletal muscle (70). 
Providing a link between the cytoskeleton inside the cell and the basement membrane 
outside of the cell, α7β1 integrin is thought to be an important mechanotransducer, and 
has been shown to be crucial for maintenance of sarcolemmal integrity. In response to 
an acute bout of eccentric exercise, young healthy mice upregulate α7, suggesting a 
role for this protein in the protection from contraction induced injury (11). To further 
investigate its role, the α7 integrin has been genetically manipulated in various animal 
models. Using an α7 knockout model (α7-/-), Rooney et al. found that following 
cardiotoxin injections to induce supra-physiological levels of damage, knockout animals 
exhibited delayed satellite cell activation and impaired regeneration when compared to 
wild type controls (113). In contrast, overexpression of α7 in a mouse model of muscular 
dystrophy (mdx/utr-/-) led to a two-fold increase in satellite cell number, and an 
enhancement in various measures of repair (15). Our lab has observed that 
overexpression of α7BX2 isoform in young healthy animals results in protection from 
damage, enhanced satellite cell activation, and accelerated myogenesis in response to 
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an acute bout of eccentric exercise (81).  Collectively, although a complete 
understanding for the role of the α7β1 integrin has yet to be realized, it is clear that this 
protein is important for the protection from damage and enhancement of regeneration in 
skeletal muscle. 
Interestingly, our lab has demonstrated that Sca-1+CD45- MSCs are increased in 
skeletal muscle (mMSCs) following an acute bout of eccentric exercise (128). Although 
we don’t fully understand the mechanisms which underlie the accumulation of mMSCs 
post-exercise, mMSC number and mMSC response to exercise appear to be α7 integrin 
dependent as they are minimally present in α7 integrin knockout mice in the sedentary 
state and increased in α7Tg mice in the sedentary state and post-exercise (128). The 
degree to which mMSCs accumulate in muscle and repair tissue in response to 
exercise with age has not been thoroughly investigated.  
 
2.7 Conclusion 
 In conclusion, sarcopenia, or the age-related loss of muscle mass and function, 
represents a major cause of disability and increased health care costs in older persons 
(68). Due to muscle’s complex nature, potential mechanisms underlying sarcopenia 
include a wide variety of factors including decreased endocrine function and sensitivity, 
chronic inflammation, denervation, and compromised vascularization  (53, 92, 113). 
Although a number of promising treatments are currently under investigation there is still 
a major effort in the scientific community to gain a better understanding of this age-
related condition with the goal of improved prevention and treatment strategies. Given 
their primary role in injured tissue repair and regeneration, mesenchymal stem cells are 
an attractive therapeutic strategy (2). In addition, α7 integrin, and it’s role in the 
prevention of damage (11, 70) as well as its association with enhanced regenerative 
responses (81), is another potential therapeutic target. The following studies will 
examine the effectiveness of both mMSC and α7 integrin based strategies, with the 
overall goal of preserving muscle mass and function over the course of the lifespan.  
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CHAPTER 3 
REVERSAL OF AGE-RELATED DECLINES IN MUSCLE FUNCTION AND 
NEUROGENESIS WITH TRANSPLANTATION OF PRECONDITIONED 
MESENCHYMAL STEM CELLS 
 
3.1 Abstract 
Mechanical strain can potently influence paracrine factor release from skeletal 
muscle-derived mesenchymal stem cells (mMSCs). Since the MSC secretome has the 
potential to impact both local and distant tissue health, the purpose of this study was to 
develop a method to promote mMSC survival and function in aged skeletal muscle.  
mMSCs isolated from young muscle were preconditioned (10% multiaxial strain, 5 hrs) 
and immediately transplanted into the muscle of 24 month old mice.  Mice receiving 
saline or non-strained mMSCs served as controls.  In addition to measuring indices of 
muscle health, the dentate gyrus of the hippocampus was evaluated for immature 
neurons 1 week post-injection.  Two weeks after transplantation, cognitive performance 
was measured by rotarod, contextual fear conditioning, water maze based tests. 
Although muscle mass, myofiber cross-sectional area, satellite cell number and 
proliferation were unchanged, vessel size and number of neuromuscular junctions were 
greater in muscle injected with strained mMSCs versus controls resulting in increased 
muscle function (P < 0.05).  A significant increase in the number of immature neurons 
(P < 0.05) and a trend towards increased cognitive function on the water maze test was 
observed in these mice. Overall, mMSC preconditioning prior to transplantation may 
provide a novel method to prevent or reverse age-related impairments in muscle 
strength, neuroplasticity, and cognitive function. 
 
 
 
 
 
 
Keywords: mesenchymal stem cell, preconditioning, skeletal muscle, neurogenesis, 
cognition 
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3.2 Introduction 
The Department of Health and Human Services Administration on Aging 
estimates there will be 72.1 million people older than 65 years by 2030 (19% of the US 
population), twice as many as in the year 2000 (1). This change in demographics has 
the potential to increase the total number of older adults suffering from age-related 
musculoskeletal and cognitive disabilities. Today, approximately 45% of individuals over 
age 75 are diagnosed with sarcopenia, defined as age-related loss of muscle mass and 
function (1). Impaired mobility as a result of sarcopenia results in inactivity and a self-
perpetuating cycle of negative net muscle mass, ultimately resulting in complete loss of 
physical function. In addition, 19% of individuals 75-84 years of age and 42% of adults 
over the age of 84 are diagnosed with Alzheimer’s disease, the most common form of 
age-related cognitive impairment (1, 26). The loss of quality of life, along with the 
impending financial burden associated with the institutionalized care of older adults, has 
stimulated a major effort in the scientific community to gain a better understanding of 
both age-related conditions with the goal of improved prevention and treatment 
strategies.  
Participation in physical activity can provide substantial protection against age-
related declines in muscle function, peripheral blood flow, and hippocampal 
degeneration (20, 21, 39, 41). The strong temporal relationship between early physical 
disabilities and mild cognitive impairment has been documented, suggesting a potential 
dependent relationship between loss of lean mass and declines in cognitive function (7, 
29). Exercise can simultaneously increase lean muscle mass and improve cognitive 
function in humans, providing a low-cost, low-risk intervention for older adults (10, 16, 
42). However, the onset of injury and disease can occur suddenly and the promise of an 
exercise intervention can become unrealistic for many individuals.   
Multipotent mesenchymal stem cell (MSCs) transplantation is currently under 
review as a potential approach for treating degenerative diseases due to their immune-
privileged nature, relative ease of isolation, and capacity for tissue repair (11, 30). 
MSCs reside within the perivascular niche of nearly all tissues, directly repairing injured 
tissue or indirectly facilitating regeneration by secreting growth and neurotrophic factors 
that can stimulate resident progenitor stem cells (2, 11). Unfortunately, stem cells from 
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young, healthy donor sources can fail to revitalize diseased and aged tissue in the 
presence of suboptimal microenvironmental cues, providing a barrier to MSC-based 
therapies (8, 30). For this reason, MSC supplementation is not currently viewed as an 
effective approach for preventing or treating age-related disabilities. 
The α7β1 integrin is a transmembrane laminin receptor that provides a physical 
link between the extracellular matrix and the inner actin cytoskeleton.  We have 
previously established that the α7 integrin, including all isoforms of the α7 integrin 
subunit, are upregulated in muscle in response to eccentric exercise in young mice, and 
that MSCs subsequently accumulate in muscle (mMSCs) in an α7 integrin-dependent 
manner (6, 40).  The most consistent phenotype associated with overexpression of the 
α7 integrin in skeletal muscle (α7 integrin transgenic mice; MCK:α7BX2; α7Tg) is 
protection from damage associated with loss of the large structural protein dystrophin 
and injury associated with an acute bout of eccentric exercise, providing speculation 
that the primary role for the α7 integrin in skeletal muscle is enhanced stabilization and 
resilience from a mechanical stimulus (5, 23). Despite the lack of damage characteristic 
of α7Tg muscle, Pax7+ satellite cells, the primary progenitor cells in muscle, are 
paradoxically increased and muscle fiber size is enhanced to a greater extent in α7Tg 
muscle compared to wild type (WT) muscle following an acute bout of exercise (23). 
Given the role for mMSCs in repair post-injury, we reasoned that mMSCs underlie the 
beneficial adaptations observed in α7Tg mice post-exercise. Indeed, our recent studies 
demonstrate that satellite cell number, new fiber synthesis and myofiber growth are 
increased in WT mice following mMSC transplantation concurrent with single and/or 
repeated bouts of eccentric exercise (44). Collectively, these studies suggest that 
mMSCs contribute to beneficial adaptations (repair, growth) associated with exercise. 
The necessary stimuli required for MSC activation, and the factors released by MSCs 
post-exercise are not known.  Despite these gaps in knowledge, we questioned whether 
MSCs isolated from skeletal muscle post-exercise could be primed to release factors 
that could overcome the barriers provided by the aged muscle microenvironment. When 
MSCs isolated from exercised muscle did not confer any advantage to aged mice, we 
began to explore other methods for increasing mMSC survival and function in aged 
tissue.   
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MSC fate, including preservation of potency and quality of the secretome, is 
determined by the milieu of chemical and structural cues present within each tissue 
environment (2, 11).  One factor that is unique and intrinsic to skeletal muscle during 
eccentric exercise is force, specifically strain or stretch associated with lengthening 
during contraction. The degree to which mMSCs in muscle naturally sense strain in 
response to exercise has not been determined, yet likely.  Therefore, in our quest to 
design a method that can promote mMSC function, we demonstrated that a single 
application of mechanical strain in vitro (10% biaxial, 1 Hz) can stimulate the release of 
factors from isolated mMSCs that are important for muscle repair and vascular growth 
(19). The release of proteins, including epidermal growth factor (EGF) and granulocyte 
macrophage colony-stimulating factor (GM-CSF), to a high degree following mechanical 
strain suggested some ability for these factors to enter the circulation and confer health 
benefits to tissues outside skeletal muscle.  Given the current studies suggesting a role 
for peripheral factors in neurogenesis, we were particularly interested in determining if 
overexpression of the α7 integrin in muscle and/or transplantation of preconditioned 
mMSCs could influence new neuron formation in the granular layer of the hippocampus.   
The identification of a stem cell in muscle that can impact systemic health would provide 
a target for strategies to promote healthy aging. 
The purpose of this study was to develop a method to promote mMSC survival 
and function in aged skeletal muscle.  Based on our previous studies, we hypothesized 
that exposure of mMSCs to an acute mechanical strain stimulus prior to transplantation 
would not only increase their survival in the aged microenvironment, but also allow for 
the sustained release of factors that would positively impact skeletal muscle strength, 
vascular function and neurogenesis.    
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3.3 Methods 
 
Animals. Protocols for animal use were approved by the Institutional Animal Care and 
Use Committee (IACUC) of the University of Illinois at Urbana-Champaign. Animals 
were fed standard laboratory chow and had access to water ad libitum. Mice were 
housed in a temperature-controlled specific pathogen-free animal room maintained on a 
12:12 light-dark cycle at the animal facility at the Beckman Institute. Three month old 
α7Tg mice (SJL/C57BL6, MCK:α7BX2) and their WT littermates were bred in house and 
used for the acute exercise study (n=20). Five week old α7Tg mice were used for all  
mMSC isolation and transplantation experiments. Aged mice (C57BL6, 24 months, 
female) were purchased (Charles River, Wilmington, MA) and used as recipients for 
mMSC transplantation (n=91). Mice were acclimated to the housing room for 1 week 
prior to the experiment.  
 
Acute Bout of Eccentric Exercise. Three month old α7Tg mice and their WT littermates 
were subjected to a single bout of downhill running exercise (-20°, 17 m/min, 30 min). 
This physiological stimulus has been established to increase the presence mMSCs in 
skeletal muscle (40). Following exercise, animals were returned to their cages and 
undisturbed for the remainder of the study. One week post-exercise, all animals were 
euthanized and tissues were collected.  
 
Isolation of mMSCs from Skeletal Muscle. Five week old α7Tg mice were subjected to a 
single bout of eccentric exercise prior to isolation of stem cells to increase yield 
necessary for transplantation. At 24 hours post-exercise, gastrocnemius-soleus 
complexes were excised and Sca-1+CD45- cells were isolated as previously reported 
(40). Briefly, after mechanical and enzymatic digestion of the dissected muscle tissue, 
filtered samples were incubated on ice with anti-mouse CD16/CD32 (1 µg/106 cells) 
(eBioscience, San Diego, CA) for 10 min in order to block non-specific Fc-mediated 
interactions. Following the block, cells were stained in a cocktail of monoclonal anti-
mouse antibodies Sca-1-PE (600 ng/106 cells) and CD45-APC (300 ng/106 cells) 
(eBioscience, San Diego, CA) diluted in 2% FBS in PBS. Fluorescence activated cell 
sorting (FACS) was performed using an iCyt Reflection System (Champaign, IL), 
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located at Carle Hospital (Urbana, IL). Negative and single-stained controls were used 
to establish gates. Sca-1+CD45- cells were collected in medium for culture (High 
glucose Dulbecco’s Modified Eagle’s Medium (DMEM), 10% FBS, 5 µg/mL 
gentamycin), and seeded on uncoated tissue culture dishes at 2.5 x 104 cells/cm2. 
Cultures were incubated at 37°C and 5% CO2 for 8 to 10 days to allow for recovery from 
the isolation protocol.  
 
mMSC Preconditioning - In Vitro Mechanical Strain. Sorted and unpassaged Sca-
1+CD45- cells were expanded to 80-90% confluence on uncoated tissue culture dishes 
and then seeded on pre-manufactured laminin peptide (YIGSR) coated, 6-well flexible 
silicone elastomer membrane plates (9.62 cm2) at 1.0 x 105 cells/well (10.4 x 103 
cells/cm2) (Flexcell International, McKeesport, PA). Cells were incubated in high 
glucose DMEM with 10% fetal bovine serum (FBS) at 37° C and 5% CO2 for 24 hours to 
allow for sufficient cell attachment. Prior to mechanical strain, cells were washed with 
warm PBS and switched to serum-free high glucose DMEM.  Equi-biaxial mechanical 
strain (10%, 1 Hz) was applied to the cells for 5 hours using a FX-4000 Flexercell strain 
unit (Flexcell International, McKeesport, PA). Cells maintained under static conditions 
were used as laminin only, non-strained controls. Three hours following the completion 
of mechanical strain, cells were detached using an accutase enzyme solution and 
collected for both in vitro and in vivo experiments. 
 
PDMS Elastomer Gel Fabrication and ECM Protein Coating. PDMS reagents (Dow 
Corning, Midland, MI) were mixed at ratios of 50:1, 40:1, and 20:1 base to curing agent. 
These ratios result in Young’s elastic moduli (E) of 10kPa, 30kPa, and 110kPa, 
respectively. Using 6-well tissue culture petri dishes, elastomers were poured to a 
thickness of 500µm to prevent the cells from sensing the stiffness of the underlying 
plastic. Following a 15 minute degassing period, gels were cured at 65°C for 3 hours. 
To allow for cell attachment, elastomers were coated with Type I collagen (BD 
Biosciences, San Jose, CA). Following a 60 minute incubation with collagen suspended 
in PBS at [100µg/mL], the gels were washed with sterile PBS and a 2% glutaraldehyde 
solution was added for 15 minutes to covalently link the protein to the PDMS elastomer. 
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Next, the elastomers were sterilized with 70% ethanol for 60 minutes. Each incubation 
period was carried out at room temperature. Finally, the gels were incubated overnight 
at 4°C in a solution of 2 mM glycine (in PBS) to quench any excess aldehyde groups.  
 
Cell Proliferation in Aged Microenvironments. Equal numbers (2.5 x 104 cells/well) of 
non-strained and strained mMSCs were DiI labeled and seeded onto PDMS gels that 
mimic both the young, healthy (E= 10kPa) and aged skeletal muscle microenvironments 
(E= 30kPa, 110kPa). Cultures were incubated at 37°C and 5% CO2 and tracked for 7 
days. Serum low conditions were used throughout the experiment (DMEM- high glucose 
+ 2% FBS). Using a grid based system to consistently image the same area of the gels, 
five10x fluorescent images were captured every 24 hours for each condition. All images 
were manually assessed for cell counts using ImageJ software (National Institute of 
Health, Bethesda, MD), and growth rates were calculated. On the seventh day of 
culture, all cells were detached using an accutase enzyme solution, and total live cell 
counts were obtained using trypan blue and a hemocytometer. Population doubling 
times (PDT) were calculated using the equation PDT = T/(log2[NF/NO]), where T= time in 
culture (hours), NO= initial number of cells on day 1, and NF= final number of cells on 
day 7 (3).  
 
Gene Expression Analysis. The detached cells from each condition were centrifuged at 
450 RCF for 5 minutes and the pellets were flash frozen in liquid nitrogen and stored at 
-80°C for later analysis. Total RNA was extracted from frozen cells using the RNeasy 
Micro Kit and QIAshredder spin columns according to the manufacturer's specifications 
(Qiagen, Valencia, CA). The RNA concentrations and purities were analyzed 
spectrophotometrically with a Synergy H1 Hybrid Multi-Mode Microplate Reader (Biotek, 
Winooski, VT). The reverse transcriptase reaction was performed using a first strand 
cDNA synthesis kit (Applied Biosystems, Grand Island, NY) according to manufacturer’s 
instructions in a thermo cycler (GeneAmp PCR Machine 9700, Applied Biosystems, 
Grand Island, NY). For detection of certain genes, cDNA was preamplified using 
TaqMan PreAmp Master Mix (Life Technologies Inc, Grand Island, NY) according to 
manufacturer’s instructions. Briefly, all stock primer/probe mixes were prediluted 
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together in Tris–EDTA buffer to give 0.2x concentration. The preamplification reagent 
comprised 25 µL TaqMan PreAmp Master Mix and 12.5 µL pooled primers mix to 0.2x 
concentration. After adding 12.5 µL cDNA, the tubes were placed in a PCR thermal 
cycler and incubated at 95°C for 10 min. Samples were preamplified for 14 cycles. The 
preamplified samples were then diluted to 1:20 with Tris–EDTA buffer. cDNA was 
stored at -20oC until qPCR analysis. Gene expression was individually quantified for all 
genes of interest using a qRT-PCR machine (7900HT Fast Real-Time PCR system and 
SDS Enterprise Database) and analyzed using the ∆∆CT method. Expression of 
GAPDH was used as the housekeeping gene. 
 
Stem Cell Transplantation. Sca-1+CD45- cells isolated from male α7Tg mice 24 hours 
post-eccentric exercise were cultured as described above in the mMSC preconditioning 
methods section. Male cells were used so that transplanted cells were sex mismatched 
and could later be identified in female recipient tissues. On the day of injection, cells 
were collected and suspended in HBSS. Intramuscular injections at a concentration of 4 
x 104 cells/50 µL HBSS were administered to both legs of 24 month old WT mice (n = 
91) while under anesthesia (1-3% isoflurane gas).  
 
Lentivirus-mediated RNAi of EGF. shRNAs in the pLKO.1-puro vector for knocking 
down EGF were purchased from Sigma-Aldrich (MISSION® TRC). The gene set 
contained five constructs with distinct target sequences, all of which were packaged for 
viral production, infection and tested for target knockdown. Clone 
NM_010113.1_1468s1c1 with ≥90% knockdown efficiency was selected for further 
study. Plasmid for scramble (control) shRNA was obtained from Addgene (Plasmid # 
1864). For viral packaging, pLKO-shRNA, pCMV-dR8.91, and pCMV-VSV-G were co-
transfected into 293T cells using Trans-LT1 (Mirus) at 0.5:0.45:0.05 µg (for a 6-well 
plate). Media containing viruses were collected 48 hours after transfection. mMSCs 
were infected with the viruses in the presence of polybrene (8µg/ml) for 16 hr and then 
subjected to selection by 2 µg/ml puromycin for 4 days prior to collection of medium or 
cell lysis.  
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Tissue Collection and Preservation. Euthanasia method varied by cohort and tissue of 
interest. At the appropriate time points, gastrocnemius/soleus muscle complexes were 
collected from CO2 asphyxiated animals. The muscles were weighed and immediately 
frozen in pre-cooled isopentane. For the collection of the brains, animals were 
anesthetized with 200 mg⁄kg intraperitoneal sodium pentobarbital and then perfused 
transcardially with 4% paraformaldehyde in phosphatebuffered saline (PBS). Brains 
were post-fixed overnight, and then transferred to 30% sucrose in PBS. Brains were 
sectioned with a cryostat into 40 µm-thick coronal sections. Sections were placed into 
tissue cryoprotectant (30% ethylene glycol, 25% glycerin, 45% PBS) in 24-well plates 
and stored at 20°C. Blood was collected from the inferior vena cava post-mortem from a 
subset of animals to analyze serum levels of EGF. Following collection, blood samples 
were centrifuged at 15,000 RPM for 10 minutes and the serum was collect, flash frozen 
in liquid nitrogen, and stored at -80°C for future analysis. All samples were collected 
either 1 week or 4 weeks post transplantation.  
 
Evaluation of Serum. For the evaluation of EGF in the serum, collected samples were 
diluted 8-fold with the kit diluent and analyzed on a mouse specific EGF ELISA plate 
(Ab100679, Abcam, Cambridge, MA). Following the manufacturers specifications, 
samples were incubated overnight at 4°C then detected with an HRP-streptavidin 
antibody on the following day. TMB one-step substrate reagent was added to each well 
and incubated for 30 minutes. After this incubation, a stop solution was added and all 
samples were immediately visualized with a Synergy H1 Hybrid Multi-Mode Microplate 
Reader (Biotek, Winooski, VT) at a 450nm wave length, and compared to a standard 
curve.  
 
Histology. Muscle complexes were divided at the midline along the axial plane, and 
embedded in OCT (Tissue-Tek; Fischer Scientific). Three transverse cryosections per 
sample (8µm non-serial sections, each separated by a minimum of 40 µm) were cut for 
each histological assessment using a CM3050S cryostat (Lecia, Wezlar, Germany). 
Sections were placed on frozen microscope slides (Superfrost; Fischer Scientific, 
Hanover Park, IL) and stored at -80°C before staining. 
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Fluorescence In Situ Hybridization. Following the manufacturer’s recommended 
protocol, 8 µm muscle tissue sections were pretreated with Tissue Digestion Kit I (KI-
60007, Kreatech, Durham, NC). Briefly, tissue sections were fixed in 100% ETOH for 1 
minute, washed with PBS, then pretreated with 0.01M sodium citrate for 15 minutes at 
97 + 1°C. Next, the sections were permeablized with a pepsin solution for 16 minutes at 
room temperature. Permeabilized sections were washed with 2x saline sodium citrate 
then dehydrated with ETOH solutions. Mouse specific X and Y chromosome probes 
(RAB9B (XqF1) directly labeled with PlatnumBright 550 (Red)/ WC Y directly labeled 
with PlatnumBright 495 (Green) (KI-30505, Kreatech, Durham, NC)) were applied to 
each section during a 5 minute denaturation step (80+1°C), then incubated overnight at 
37°C in a humidified chamber. On the second day, a number of washes were performed 
followed by a DAPI counterstain. Transplanted cells were identified by the presence of 
the Y chromosome.  
 
Immunohistochemistry. For all antibody based stains the frozen tissue sections were 
fixed in ice-cold acetone for 10 min and blocked with PBS containing 5% bovine serum 
albumin (BSA) followed by 70 µg/ml AffiniPure anti-mouse Fab fragments diluted in 5% 
BSA (Jackson ImmunoResearch Laboratories, West Grove, PA) for 20 and 30 min, 
respectively. 
 
To assess skeletal muscle growth, tissue sections were co-stained with Pax7 (mouse 
hybridoma, 1:2) and dystrophin antibodies (ab15277, 1:100) (Abcam, Cambridge, MA). 
Pax7 expression was used to identify satellite cells while dystrophin was used to identify 
the sarcolemma to allow for cross-sectional area measurements. Both primary 
antibodies were diluted to the appropriate concentration in 1% BSA, and were 
independently applied to the tissue sections for 4°C overnight and 60 minutes at room 
temperature incubations, respectively. Fluorescein isothiocyanate (FITC)-labeled 
donkey anti-mouse (1:250), and tetramethyl rhodamine isothiocyanate (TRITC)-labeled 
goat anti-rabbit (1:100) secondary antibodies (Jackson ImmunoResearch Laboratories, 
West Grove, PA) were used to detect the Pax7 and dystrophin antibodies, respectively. 
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A DAPI stain was added to the second to last wash step (1:20,000) (Sigma Aldridge, St. 
Louis, MO) to allow for nuclei identification. 
 
To assess skeletal muscle vascularity, tissue sections were stained with a CD31 
monocolonal antibody (eBioscience, San Diego, CA) for the detection of endothelial 
cells. Co-staining with a dystrophin monoclonal antibody (Sigma Aldridge, St. Louis, 
MO) was performed for localization and myofiber cross-sectional area measures. Both 
primary antibodies were diluted to a concentration of 1:100 in PBS with 1% BSA, and 
were independently applied to the tissue sections and for an incubation period of 60 
minutes at room temperature. FITC-labeled donkey anti-rat (1:250), and TRITC-labeled 
goat anti-mouse (1:100) secondary antibodies (Jackson ImmunoResearch Laboratories, 
West Grove, PA) were used to detect the CD31 and dystrophin antibodies, respectively  
 
To assess neuromuscular junction stabilization sections were co-stained with α-
bungarotoxin conjugated with Alexa Fluor 488 (1:100) (Invitrogen, Grand Island, NY), 
and an anti-synaptophysin antibody (1:100) (Millipore, Billerica, MA). The anti-
synaptophysin, which recognizes pre-synaptic vesicle proteins, was visualized with a 
TRITC-labeled goat anti-rabbit (1:100) secondary antibody (Jackson ImmunoResearch 
Laboratories, West Grove, PA). Co-localization of these markers was used to measure 
proper pre- and post-synaptic neuromuscular junction structure alignment within skeletal 
muscle.   
 
One separate one-in-six series of sections throughout the rostrocaudal extent of the 
brain, with 240 µm increments separating each section, was stained with DCX-DAB to 
detect immature neurons. Free-floating sections were washed in phosphate-buffered 
solution (PBS) and treated with a solution of .3% Triton-X and 6% normal donkey serum 
(NDS) in PBS (PBS-X plus 6% NDS) for 60 min. Sections were then incubated in a 
PBS-X plus 6% NDS solution with primary antibody goat anti-DCX (1:1000, Santa Cruz 
Biotechnology, TX) at a dilution of 1:1000 for 48 hr at 4°C. Sections were then blocked 
with a solution of PBS-X plus 3% NDS for 20 min and incubated in biotinylated 
secondary antibody donkey anti-goat (1:200; Santa Cruz Biotechnology) in a solution of 
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PBS-X plus 3% NDS for 90 min. Sections were then washed in a solution of 0.3% 
Triton-X in PBS and treated with the ABC system for 60 min (Vector Laboratories, 
Burlingame, CA), then stained with a DAB kit (Sigma Aldrich, MO, USA). 
 
Image Analysis. All fluorescently stained tissues were visualized on an upright inverted 
fluorescent microscope (Zeiss, Thornwood, NY), excitation source (X-Cite 120, EXFO, 
Ontario, Canada), and with the appropriate filter sets. Images were captured with a 
Ziess AxioCam digital camera and Axiovision software (Zeiss, Thornwood, NY). A 
combination of Adobe Photoshop (CS5 Extended) and ImageJ plug-ins and tools were 
used to analyze and quantitate all images acquired. For evaluation of Pax7+ satellite 
cells, and cross-sectional areas (CSA), a total of 20 digital images acquired at 40X 
magnification were captured at random from each sample. Images were acquired in 
separate color channels to allow for independent analysis of TRITC (red), FITC (green), 
and DAPI (blue) images. Total numbers of Pax7+ co-localizing with DAPI, total 
myonuclei, and CSAs were assessed on all images as previously described (Huntsman, 
2013). 
 
To thoroughly assess changes in skeletal muscle capillarization a total of 20 digital 
images acquired at 40X magnification were captured at random from each sample. 
Images were acquired in separate color channels to allow for independent analysis of 
FITC (green) and TRITC (red) images. The CD31-FITC images were first analyzed for 
total number of transversely cut capillaries, as indicated by punctate, single cell staining, 
with the ImageJ template matching plug-in. Finally, the dystrophin-TRITC images were 
imported into Adobe Photoshop (CS5 Extended) where an average of 500 fibers per 
sample were manually circled using the magnetic lasso tool to decrease subjectivity and 
inter-assessor error by grabbing the positively stained pixels. Cross-sectional area 
measurements from each myofiber were recorded in the measurement log. From these 
data capillary density was calculated as total number of capillaries to area of tissue 
assessed.  
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For the evaluation of vessels further up the arterial tree, the entire muscle section was 
analyzed for CD31+ vessels. Inclusion criteria for positive large vessels were as follows, 
1) specific CD31 staining, 2) a visible lumen, and 3) a vessel diameter ranging from 5 to 
approximately 70 µm. All vessels were analyzed for vessel and lumen diameter using 
Adobe Photoshop CS5. Data are reported as both a mean number of total vessels 
greater than 5 µm, and percentage of total vessels assessed by size to show the 
distribution of various vessel sizes.   
 
For the evaluation of neurogenesis within the granular layer of the dentate gyrus, total 
numbers of DCX-DAB cells were assessed. The number of immature neurons (marked 
by DCX-DAB) per mouse was calculated as number of DCX positive cells per coronal 
section of granule layer. To obtain these estimates, the entire granule layer (bilateral), 
from the one-in-six series stained for DCX-DAB, was imaged by systematically 
advancing the field of view of a Zeiss brightfield light microscope, and taking multiple 
photographs, via Axiocam interfaced to a computer, under 10× (total 100×) 
magnification. Images were analyzed by ImageJ software. For each image, the granule 
layer was outlined, and DCX-positive neurons were counted by hand within the outlined 
area. In addition, the area (pixels) within the trace was recorded. Total number of pixels 
was then converted to square microns using the internal calibration with Axiovision 
(Zeiss software). This area was then multiplied by 40 microns between sections to 
estimate volume in cubic microns, which was then divided by the total cell count to 
determine density of DCX positive cells. Estimates of total number and density of DCX 
positive cells are adjusted by removing the fraction of cells (15%) predicted to cross the 
boundary of the section on one side to produce unbiased estimates. 
 
Grip Strength. Grip strength measurements for all four limbs were tested pre- and 1 
week and 4 weeks post-transplantation using an electronic Grip Strength Meter 
(Columbus Instruments, Columbus, OH). All mice were acclimated to the procedure for 
three days prior to data collection. Briefly, mice were passed over a metal mesh grid 
connected to a force transducer and were given the opportunity to grab the grid with all 
fours limbs. The mice were then pulled away from the force transducer, and parallel to 
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the grid at a constant rate until volitional release of the grid. The peak force in grams 
was recorded over the course of three independent trials. All measurements were 
performed by the same examiner who was blinded to the treatment of the animal.  
 
Maximal Isometric Force. Maximal force was measured using a dual-mode lever 
system. Briefly, mice were fully anesthetized with 1-3% isoflurane gas before electrical 
stimulation of the sciatic nerve at 10 mA for 1.5 seconds (250 Hz). Muscle forces were 
collected using a servomotor and analog control unit (model 305C-LR, Aurora Scientific, 
Aurora, ON). Stimulation was repeated nine times with 5-s recovery periods, for a total 
of 10 measurements. The values of maximal force output were normalized to muscle 
mass (g/g). 
SPECT-CT Imaging and Vascular Function. Hind limb blood flow was assessed at three 
separate time points on a subset of animals (n=15) using single-photon emission 
computed tomography – computed tomography (SPECT-CT). molecular imaging 
techniques. Mice were anesthetized with 1–3% isoflurane, and the left jugular vein was 
surgically exposed to facilitate injection of the radiotracer 99mTC-tetrofosmin. Imaging 
was performed using a hybrid small animal SPECT-CT scanner (Inveon, Siemans 
Scanner, Erlangen, Germany), with 20 SPECT and 360 CT projections captured per 
animal for a total of ~30 minutes of scanning time. Animals were scanned 1 week prior 
to cell transplantation to establish flow baselines, as well as 1 and 4 weeks post-
transplantation to assess the effect of treatment. Three days after the last imaging 
session, to allow for complete radioactive decay of the radiotracer animals were 
euthanized with CO2 asphyxiation and tissue were collected. All scans were analyzed 
using Inveon Research Workspace software (Siemans, Erlangen, Germany), where CT 
images were used for anatomical localization and determining standardized region of 
interest cut points, and SPECT images were analyzed for maximal radioactivity in the 
lower limb. All values are reported as relative changes, with baseline flow values from 
each animal being it’s own normalizer.  
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Cognitive Function. All behavioral testing was done during the dark phase of the light 
cycle to accommodate for enhanced activity during this phase.    
 
Home Cage Activity. To evaluate endogenous locomotion, mice were placed individually 
in custom-made acrylic home cages (18.5 cm × 33.5 cm × 16 cm) with clear plastic lids 
conducive for video tracking from above for 5 days. Food and water were delivered from 
the side so the mouse was visible in all areas of the cage when viewed from above. A 
clear divider separated adjacent cages so mice could not interact, but could see one 
another. Corncob bedding (Harlan 7097; Harlan-Teklad, IN) was lined the bottom of 
each cage. Video cameras mounted on the ceiling of the animal room provided 
continuous video feed into two separate computers running TopScan video tracking 
software (Clever Sys Inc, VA). Video tracking allowed continuous monitoring of all 
animals for the entire duration of home cage activity evaluation. White lights were 
placed under the tables holding the cages to produce diffuse light during the light phase 
and were controlled with a timer set to a 12:12 L:D cycle. Red lights were placed around 
the room to illuminate cages during the dark phase for continuous video tracking. 
Distance travelled was defined by movement of the center of mass of the animals (1 
mm resolution) and was recorded on days 3 and 4 of the 5 days in the home cages 
using TopScan video tracking software. Distance traveled was evaluated using days 1 
through 4 because day 5 was not a full 24 hours. 
 
Rotarod, After water maze, mice were tested for performance on a rotarod (AccuRotor 
Rota Rod Tall Unit, 63-cm fall height, 30- mm diameter rotating dowel; Accuscan, OH, 
USA). Mice were tested for performance on the rotarod for four consecutive trials per 
day for 2. The trial began with the dowel starting at 0 rpm and accelerated constantly at 
60 rpm/min. The timer was automatically stopped when the mouse fell off the dowel and 
broke a photobeam at the base of the rotarod apparatus.  
 
Contextual Fear Conditioning. Following rotarod, mice were tested for contextual fear 
conditioning. Mice were divided into groups, shock  (n=9/group) or control (n=3/group), 
across treatments. All mice were placed into a fear conditioning chamber for 180s on 
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day 1 and day 2. On day 1, mice in the shock group received 2 foot shocks (0.5 mA, 2 s 
duration) at 120 s and 150 s. Mice in the control group did not receive any foot shocks. 
On day 2, all mice were placed into the chamber in the absence of any foot shock. The 
chamber consisted of a plastic cage (dim 32×28×30 cm L×W×H) with a wire grid bottom 
connected to a shock scrambler controlled by a digital timer (Med Associates,  VT, 
USA). The animal’s movement was tracked with a video camera mounted to the ceiling 
using TopScan video tracking software. Freezing was measured as the percent total 
number of seconds when the animal’s center of mass did not register horizontal 
movement, as tracked by TopScan (±1 mm).  
 
Water Maze. Mice were trained on a water maze with two trials per day for 5 days. 
Trials lasted either 60 seconds or after the mouse had reached the platform and 
remained there for 10 seconds. If a mouse did not reach the platform in 60 seconds, it 
was gently led to the platform by hand and remained there for 10 seconds. Mice were 
placed back in their cage and allowed to rest for 5 minutes between trials. One hour 
after training on day 5, the platform was removed and mice were tested with a 60 
second probe trial. The maze was a circular tank (70 cm diameter, 20 cm height), filled 
to a depth of 15 cm and white Crayola tempera paint was added to make the water 
opaque so the platform could not be seen. The platform consisted of a white plastic 
mesh circle (10 cm diameter) to match the color of the water, which was placed in the 
middle of one quadrant of the maze and submerged 0.5 cm below the surface of the 
water. Water temperature was maintained at 25°C (±1°C). Extra-maze cues were 
placed around the room to facilitate learning. All trials were tracked using TopScan 
video software to evaluate path length to the platform (1 mm resolution), swim speed 
(meters per second), and duration spent swimming to the platform or in the maze 
(during probe trial only). For the probe trial, a computer profile of the maze divided the 
tank into four even quadrants to evaluate the aforementioned measures. 
 
Statistical Analysis. All data were averaged and presented as means + standard error, 
and were analyzed using SPSS (20.0, Chicago, IL) or Statistical Analyzing Software 
(9.2, Cary, NC). Differences were considered significant at p<0.05. All in vitro cell data 
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were analyzed by two-way analysis of variance (ANOVA) with treatment (no strain vs. 
strain), substrate stiffness, and the interaction of treatment and substrate stiffness as 
factors.  
 For all local tissue adaptations (satellite cell percentage and proliferation, 
innervation percentage, and CD31+ vessel number and distribution) one-way ANOVA 
analyses were performed with treatment as the factor. Grip strength and blood flow data 
were analyzed by repeated measures ANOVA with treatment as the between-subjects 
factor and time point as the within-subjects factor. For maximal isometric force data, 
polynomial regression was used to compare the force curves between treatment 
groups. Tukey’s post hoc analyses were used to compare the means between groups. 
 For α7Tg experiments, numbers of DCX+ cells were analyzed by two-way ANOVA 
with genotype, exercise, and the interaction of genotype and exercise as factors. When 
main effects were detected, Tukey’s post hoc analyses were performed. Correlations 
between serum EGF and total DCX+ numbers were estimated as Pearson’s r. 
 To verify the knockdown model EGF gene expression data were analyzed with an 
independent T-test. Serum EGF concentration was analyzed by one-way ANOVA with 
treatment as the factor. Neurogenesis was measured as total numbers of DXC+ cells in 
the granular layer of the hippocampus. Numbers of DCX+ cells were analyzed by one-
way ANOVA with treatment as the factor. Home cage activity, rotarod, and water maze, 
were analyzed by repeated measures ANOVA with treatment as the between-subjects 
factor and day as the within-subjects factor. Tukey’s post hoc analyses were used to 
compare the means between groups. 
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3.4 Results 
Mechanical Strain Preconditioning Influences mMSC Growth Rate and Sustains the 
Release of Growth Factor  
 mMSCs were exposed to a single application of mechanical strain and 
immediately seeded onto PDMS elastomer gels created to mimic the stiffness of young 
healthy (E=10kPa) and aged skeletal muscle microenvironments (E=30kPa & 110kPa). 
mMSC numbers were evaluated every 24 hours for 7 straight days. Strained mMSCs 
expanded at a slower rate than non-strained cells during the 7 day period (F1,31 =18.0, 
p<0.001), with an interaction of stiffness and strain (F2,31=4.5, p=0.02) (Figure 3.1A). 
This effect resulted in slower population doubling times for all strained cells as 
compared to the non-strained controls (E=11kPa: 164+26 hrs vs. 93+7 hrs, E=30kPa: 
140+12 hrs vs. 97+4 hrs, and E=110kPa: 119+15 hrs vs. 114+5 hrs). Despite the slower 
rate of expansion, the total number of preconditioned cells present at the end of one 
week increased as a factor of enhanced stiffness, whereas the opposite behavior was 
observed in the non-strained control cells (Figure 3.1B). After the 1 week expansion 
period, mMSC gene expression was evaluated.  mMSC EGF and hepatocyte growth 
factor (HGF) mRNA was higher in preconditioned cells compared to non-strained cells 
independent of stiffness (F1,32=52.1, p<0.001 and F1,32=21.28, p<0.001, respectively) 
(Figure 3.1C-D). Vascular endothelial growth factor α (VEGFα) mRNA was not altered 
one week later (F1,32=2.5, p=0.119) (Figure 3.1E). 
 
mMSCs are Present in Aged Skeletal Muscle Post-Transplantation and Improve Local 
Tissue Health 
 The presence of mMSCs isolated from male donors was identified in female host 
tissue by the presence of the Y chromosome (Figure 3.2). Preconditioned 
(mMSC+Strain) and non-strained (mMSC) mMSCs were present in skeletal muscle at 1 
week post transplantation. Despite efforts to evaluate mMSC survival, not all nuclear 
membranes effectively permeabilized to allow for antibody access to X and Y 
chromosomes and a quantitative comparison between groups was not possible. 
 Pax7+ satellite cell number (normalized to total myonuclei) and the percentage of 
proliferating satellite cells were evaluated 1 week post transplantation in aged mice 
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injected with saline, mMSCs or mMSCs+Strain (Figure 3.3A-D).  No significant 
differences were detected (p>0.05). In agreement with these data, no differences in 
body weight, muscle mass or myofiber cross-sectional areas were observed (Figure 
3.3E-H).  
Alignment of pre-synaptic (synaptophysin) and post-synaptic (α-bungarotoxin) 
proteins varied by treatment (F2,24=5.4, p=0.012), and was present to a greater degree 
in the mMSCs+Strain group as compared to the Saline group (p<0.01), suggesting 
preservation of the neuromuscular junction in aged skeletal muscle (Figure 3.4A-B). 
 Grip strength is a non-invasive and repeatable measure of hind limb function. 
Using this test, the mMSCs+Strain group experienced slight gains in strength 1 week 
post transplantation, whereas the other groups experienced slight decrements at this 
same time point. At 4 weeks post transplantation, a significant treatment effect was 
observed (F2,15=3.9, p<0.05), and was significantly increased in mMSCs+Strain 
compared to Saline (p< 0.05) (Figure 3.4C).  
 Maximal isometric force of the plantar flexors was measured at 4 weeks post-
transplantation in a subset of animals.  Although there was no difference in maximal 
force between groups, polynomial regression analysis revealed a treatment effect 
(F2,45=3.4, p<0.05), with a  significant upward shift in the force curve of mMSCs+Strain 
as compared to mMSCs (p<0.05) (Figure 3.4D). This effect is also apparent when 
percentages of maximal force achieved in the final stimulation are compared between 
groups (Saline: 39.6+3.4%, mMSCs: 39.8+2.9%, and mMSCs +Strain: 46.1+3.2%) 
(data not shown).   
 
mMSC Transplantation Affects Vessel Size within Skeletal Muscle 
 We previously reported that the transplantation of mMSCs into skeletal muscle of 
young mice could indirectly and positively influence vessel growth through the release 
of factors such as GM-CSF, VEGF, fibroblast growth factor (FGF), and placental growth 
factor (PlGF) (19). The total number of CD31+ vessels less than 5 µm was not different 
between groups at 1 week post transplantation (Figure 3.5A). Although total numbers 
of CD31+ vessels greater than 5µm did not change significantly at this same time point 
(Figure 3.5B), a rightward shift in the distribution of vessel size was observed in 
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mMSCs+Strain compared to both control groups (Figure 3.5C). Whether these 
observed changes could influence perfusion was assessed using a molecular based 
imaging technique (SPECT-CT) (Figure 3.5D). Although these functional data mirror 
the histological assessment, no significant differences in perfusion were observed 
between groups (Figure 3.5E).  
 
Correlation Between mMSCs and Neurogenesis 
 Previously, our lab has established that a single bout of downhill running can 
increase the accumulation of mMSCs in skeletal muscle (2-fold vs. no exercise control) 
and transgenic expression of the α7 integrin in muscle can enhance this effect (4-fold vs. 
no exercise control) (40).  We have also established that mMSCs in isolation can 
synthesize and release EGF in response to mechanical strain, a factor that can 
influence neuroplasticity (19).  Thus, serum EGF and neurogenesis were evaluated in 
WT and α7Tg mice 24 hours following an acute bout of eccentric exercise.   Serum EGF 
levels varied significantly by exercise condition (F1,18=9.7, p=0.007), with an interaction 
between exercise and genotype (F1,18=8.1, p=0.012). Post-exercise, α7Tg animals had 
significantly higher serum EGF levels compared to all other groups (p<0.05) (Figure 
3.6A). Doublecortin (DCX) was used as an early marker of immature neurons (Figure 
3.6B). A main effect for exercise was observed for DCX+ cell number (F1,18=5.7, 
p=0.0275) (Figure 3.6C). When normalized to hippocampal volume, the exercise effect 
(F1.18=2.8, p=0.107), was slightly mitigated (Figure 3.6D). Interestingly, serum EGF 
concentration correlated strongly with DCX+ cell number for α7Tg mice in the sedentary 
state and post-exercise (Pearson’s r= 0.91; p<0.05) (Figure 3.6E).  
 
Neurogenesis Observed in Aged Preconditioned Cell Transplant Recipients is EGF 
Independent 
Studies were conducted to determine the extent to which mMSC preconditioning 
prior to transplantation could influence neurogenesis in aged recipients, and additionally 
evaluate a role for EGF in this event. An EGF shRNA lentivirus transfection model was 
chosen to inhibit the production and release of EGF in a subset of mechanically strained 
mMSCs (Figure 3.7A). To confirm the knock down efficiency in these cells, qRT-PCR 
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was used to compare gene expression levels between the knock down (shRNA_EGF) 
and control cells (Scrambled RNA Control).  Using this construct we were able to 
achieve a 60% knock down in the shRNA_EGF cells (t4=3.3, p<0.05) (Figure 3.7B). To 
determine whether this resulted in lower levels of circulating EGF protein, ELISA based 
analysis of the serum was performed. In agreement with the qRT-PCR data, 
significantly lower levels of EGF were detected in the animals receiving the 
shRNA_EGF transfected cells when compared to the control cells (p<0.05) (Figure 
3.7C).  
Next, the hippocampus from each animal was analyzed for DCX expression 
within the granular layer (Figure 3.8A). Both total numbers and density of DCX+ cells 
varied significantly by treatment group (F4,26=2.9, p=0.03 and F4,26=3.7, p=0.015, 
respectively) (Figure 3.78B-C). Interestingly, when comparing all mechanically strained 
cell groups (shRNA_EGF, Scrambled RNA Control, and mMSCs+Strain) significant 
increases in numbers of DCX+ cells were observed when compared to non-strained 
mMSCs (shRNA_EGF and Scrambled RNA Control vs. mMSCs p<0.05, mMSCs+Strain 
vs. mMSCs p=0.06). Trends for an increase were observed in shRNA_EGF and 
Scrambled RNA control as compared Saline (p=0.054 and p=0.073, respectively) 
(Figure 3.8B). These same observations held true when normalizing to total volume of 
the hippocampus (Figure 3.8C).    
 
Neurogenesis Improves Cognitive Function in Aged Animals 
  To determine whether these central nervous system adaptations were 
associated with any functional gains, a series of cognitive tests were performed. The 
battery of tests chosen included both hippocampus dependent and independent tests. 
First, because of the known correlation between physical activity and cognition, daily 
locomotion was tracked over the course of 4 consecutive days. Analysis of the average 
daily locomotion on days 3 and 4 showed no differences in the activity level between the 
groups (p>0.05) (Figure 3.9A). Next, balance and episodic memory were assessed with 
rotarod and contextual fear conditioning tests, respectively. Both being hippocampus 
independent behaviors, again no differences were observed between the groups 
(p>0.05) (Figures 3.9B-C). Finally, when the groups were compared on their 
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performance on hippocampus dependent behaviors, a trend for an increase in spatial 
memory tasks was observed in the time spent in the target quadrant (F2,32=2.8, 
p=0.0701) (Figure 3.9D-E). 
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3.5 Discussion 
 Our previous work has established that mMSCs accumulate in skeletal muscle in 
an α7 integrin-dependent manner (40), and that these cells, through paracrine factor 
release, significantly enhance muscle repair and vessel growth in young healthy tissue 
(19). Unfortunately, the aged microenvironment can impair endogenous mMSC function 
and subsequently contribute to the degeneration and loss of muscle mass and strength 
observed over the lifespan (9, 34).  Developing strategies to either preserve 
endogenous mMSC function or increase the success of stem cell-based therapies are 
necessary to prevent or treat age-related disabilities. The purpose of this study was to 
determine the extent to which mechanical strain could preserve mMSC function in the 
aged microenvironment and improve local and distal tissue health following 
transplantation.  The results from this study demonstrate that mechanical strain 
preconditioning can improve the contribution of mMSCs to muscle strength and 
neurogenesis in aged mice.   
 Aged and diseased tissues are enriched with collagen, fat, and proinflammatory 
cytokines that limit regeneration and growth of tissue (8, 14, 24).  While allogeneic stem 
cell transplantation from a healthy donor would appear to be a reasonable approach 
towards improving repair and tissue health, donor stem cells often do not survive or 
become dysfunctional in the presence of these environmental cues.  Therefore, 
significant effort is now focused on studying the interaction between stem cells and a 
variety structural, chemical, and pharmacological cues for the purpose of enhancing 
endogenous stem cell health, or developing preconditioning methods that can ensure 
stem cell survival following transplantation (30).  Due to the mechanical nature of 
muscle microenvironment, and our previously published data demonstrating that 
mMSCs are highly sensitive to force provided by mechanical strain, we hypothesized 
that mechanical strain could be used as an effective preconditioning method to improve 
the therapeutic outcome associated with mMSC transplantation in aged skeletal muscle.  
The mechanical strain preconditioning method was first tested in this study in 
vitro using PDMS gel elastomers that allow for adjustment of stiffness and substrate to 
mimic the young, healthy and aged skeletal muscle microenvironments.  Stiffness was 
chosen as the modulating variable due to the well-established relationship between 
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stiffness and tissue health (i.e. tissue increases in stiffness with advanced age and 
disease state) (31), and the fact that increased stiffness can result in inappropriate or 
unexpected stem cell behavior (15).  In this study we found that mechanical strain 
enhanced mMSC EGF and HGF mRNA expression compared to non-strained cells and 
gene expression was not altered in the presence of a stiff environment up to 1 week 
later (Figure 3.1C-D). Interestingly, while increasing stiffness decreased the growth 
rates of non-strained cells, the opposite behavior was observed in the strained mMSCs 
(Figure 3.1A-B). These data suggested that mMSCs were responsive to mechanical 
strain in a manner that enhanced function, even in the presence of conditions 
associated with aging.  
 The success of the in vitro experiments prompted us to evaluate our hypothesis 
in vivo. Preconditioned mMSCs (4.0 x 104) were directly injected into the 
gastrocnemious/soleus complex of 24 month old mice and satellite cell number and 
proliferation were examined at 1 week post-injection as measures of regeneration 
potential. Despite the fact that prior studies, including our own, suggested that injury 
was necessary for mMSC-mediated improvements in satellite cell number, a decision 
was made to not exercise or injure aged recipients as accumulation of damage is a 
hallmark of aged muscle tissue (8). Unfortunately, we did not observe significant 
increases in satellite cell percentage or proliferation (Figure 3.3A-C). There are several 
factors that may have contributed to the lack of satellite cell expansion, including the 
absence of injury and necessary cues necessary to promote mMSC contribution to 
repair, the time point chosen for observation (1 week post-injection), and the quantity of 
mMSCs injected (4 x 104). Currently, the timeline for satellite cell accumulation in 
rodents or humans following mMSC transplantation in the presence or absence of injury 
has not been determined.  However, studies suggest that the time course for satellite 
cell activation is delayed (72 hr) in older versus younger (24 hr) adults following an 
acute bout of resistance exercise (13, 18, 37).  Although a time course study was not 
feasible in this study, future studies should attempt to address this question.  
 Muscle force was evaluated using two methods, including a single assessment of 
maximal isometric force at the end of the 4 week testing period and comparative 
assessment of non-invasive grip strength before and after transplantation.  
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Preconditioned mMSCs not only shifted the entire force curve upward, but also 
appeared to preserve maximal isometric force with repeated stimulus, suggesting some 
protection from fatigue. Injection of non-treated mMSCs shifted the isometric force curve 
downward, suggesting the potential for these cells to negatively affect strength.  
While isometric force provides an indication of intrinsic muscle strength, 
independent of nerve health, grip strength can reflect changes in strength due to both 
muscle and nerve health. Interestingly, hind limb grip strength was significantly 
improved in aged mice 4 weeks post-transplantation.  The fact that aging can result in 
denervation prompted us to evaluate neuromuscular junctions in muscle 1 week post-
transplantation (12).  The percentage of properly aligned pre- and post-synaptic proteins 
was higher in the muscle treated with preconditioned mMSCs compared to saline. 
(Figure 3.4A). The preservation of the neuromuscular junction provides support of 
improved nervous system function.  Whether mMSCs directly or indirectly contribute to 
nerve function was not determined in this study.  However, IGF-I can prevent neuronal 
death and increase NMJ formation in muscle (25, 27, 28).  Thus, support of nerve 
function, via mMSC release of IGF-1 and/or other neurotrophic factors, may provide the 
basis for changes in function in the absence of overt changes in skeletal muscle growth 
in this study. 
 Equally important to the function of skeletal muscle is sufficient delivery of blood 
supply. For this reason we wanted to thoroughly assess the effect of transplantation on 
vessel growth. Similar to our observations in young tissue (19), mMSCs did not 
contribute to angiogenesis (number of vessels < 5 µm) (Figure 3.5A-B), but did result in 
a rightward shift in the size distribution of larger vessels (number of vessels > 5 µm) 
(Figure 3.5C). The change in vessel growth, which was enhanced but not significantly 
increased in this study, likely reflects a remodeling event driven by the increased 
presence of several factors important for endothelial cell proliferation such as VEGF, 
PlGF, and GM-CSF, all of which are released from mMSCs. In support of this 
hypothesis, Beckman et al. found that shRNA_VEGF transfection of mechanically 
strained muscle derived stem cells (MDSC) inhibited the total number of CD31+ cells 
found in mdx/scid mouse muscle compared to non-transfected mechanically strained 
MDSC recipients 2 weeks post-transplantation (4).  
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The extent to which changes in blood vessel morphology can influence hind limb 
perfusion was addressed in our study using SPECT-CT.  A 40% increase in flow was 
detected in the preconditioned mMSC group at 4 weeks post-transplantation (Figure 
3.5E).  Although this change was not statistically significant, the fact that mMSCs could 
enhance perfusion to a small degree is noteworthy and suggests some opportunity for 
these cells to improve vascular health (17).  
The primary purpose for injecting preconditioned mMSCs into skeletal muscle 
was to reverse some of the decrements in regeneration, growth and function commonly 
observed in this tissue type with age.  We were encouraged by the changes we 
observed, both less and more significant, given the consistency of change in a positive 
direction and the fact that aged tissue does not easily adapt to treatment. The results 
from these experiments prompted us to examine the presence of growth factor in the 
circulatory system and examine the potential for stem cells to impact distal tissue 
health.  Our in vitro studies suggested that mMSCs are sensitive to the stimulus 
provided by mechanical strain and secrete EGF to a large degree (4-fold) compared to 
non-strained cells (19).  While the receptor for EGF is ubiquitously expressed in a 
number of cells for the purpose of promoting cell proliferation, cell differentiation, and 
survival, studies suggest it can stimulate new neuron formation and enhance 
proliferation of oligodendrocytes, as well as increase long-term potentiation of neurons 
in the brain (33, 36, 38).  Our proof of principle experiments using α7Tg mice were 
successful, demonstrating that muscle enriched with mMSCs respond to exercise by 
secreting EGF as detected in the serum (Figure 3.6A), and that this event is correlated 
with a significant increase in the number of newly formed neurons in the hippocampus 
(Figure 3.6E).  Intramuscular injection of mMSCs similarly increased DCX+ cell number 
in the hippocampus, although EGF knockdown did not impact this event (Figure 3.8B).  
The ability for EGF to influence neurogenesis in the subventricular zone (SVZ) of the 
lateral ventricles was not evaluated, nor the oligodendrocyte population, both which are 
established EGF targets (22, 33).  Nonetheless, the induction of new neuron formation 
in the hippocampus mirrored similar, yet slightly less significant, improvements in 
cognitive function (Figure 3.9D).  Transplantation of larger numbers of mMSCs, as well 
as increased numbers of recipient mice may be necessary for future studies.  In 
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addition, whether EGF knockdown impacted the muscle or other cell types in the brain 
will be important for elucidating a role for the EGF in mMSC-based therapies. 
 The results from this study suggest that physical force, in the form of mechanical 
strain, has the ability to increase mMSC contribution to muscle and brain function.  An 
interesting question that has evolved from this study is whether mMSCs underlie 
improvements in strength and cognition that occur with exercise throughout the lifespan.  
If true, one might speculate that the mMSC response to routine exercise may provide 
the cellular basis for protection against muscle atrophy and declines in memory and 
learning with age.  Studies suggest that brain-derived neurotrophic factor (BDNF) is 
secreted by skeletal muscle that can significantly impact neurogenesis (42).  Selectively 
evaluating a direct relationship between paracrine factor release, including 
combinations of factors such as EGF and BDNF, and tissue health will be a challenge.  
However, high-throughput screening methods and methods that allow for modulation of 
gene expression make this a more realistic goal now than ever before.  Understanding a 
role for stem cells in the conditions of health and disease is both timely and necessary.  
 In conclusion, this study provides an initial evaluation of a preconditioning 
method that can improve MSC survival and function in aged skeletal muscle following 
transplantation.  Whereas pretreatment of muscle-derived MSCs with mechanical strain 
did not improve the ability for MSCs to stimulate regeneration at 1 week, early changes 
in NMJ alignment were observed and may provide the basis for increased muscle 
strength post-transplantation.  The unexpected finding in this study was the ability for 
preconditioned MSCs to not only increase local tissue function, but additionally 
stimulate new neuron formation in the hippocampus.  Further studies are necessary to 
elucidate the basis for communication between mMSCs and the hippocampus, as well 
as determine the extent to which mechanically stimulated mMSCs provide the basis for 
improvements in whole body health with exercise throughout the lifespan.   
 
 
 
 
 
 69 
3.6 Figures and Figure Legends 
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Figure 3.1. Effects of mechanical strain on cell growth rates and growth factor release. 
(A) mMSCs were tracked in vitro, and 5 images per culture were captured daily for seven 
consecutive days (n=6/nonstrain condition, n=5/strain condition). From these images, growth 
kinetics were calculated. (B) On the seventh day of culture, all cells were detached and total 
numbers of live cells were determined. A significant effect of strain and an interaction of 
strain and substrate stiffness were observed (p<0.001). (C-E) mRNA was extracted from 
mMSCs on day seven and relative gene expression of epidermal growth factor (EGF), 
hepatocyte growth factor (HGF), and vascular endothelial growth factor α (VEGF-α) were 
compared between treatments. (C) Significant main of effects of strain and stiffness 
(p<0.001) and an interaction of these two factors (p=0.008) were detected in EGF 
expression. (D) A significant main effect of strain was detected in HGF expression levels. (E) 
The strain effect on VEGF-α expression (p=0.119) did not reach significance. All gene 
expression data are presented as relative to the nostrain 11kPa treatment group.  	  
Figure 3.2. mMSCs survive transplantation into aged skeletal muscle. The presence of 
mMSCs isolated from male donors was identified in female host tissue by the presence of 
the Y chromosome (n=8-9/treatment). Above are representative images of muscle injected 
with saline (left) and of muscle transplanted with mMSCs+Strain (right). All images were 
captured at x100 magnification (scale bar = 5µm). The X chromosome was directly labeled 
with a PlatinumBright 550 probe (red), where as the Y chromosome was labeled with a 
PlatinumBright 495 probe (green) using FISH. 	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Figure 3.3. Traditional measures of muscle regeneration do not change resulting in 
no gains in muscle mass or myofiber cross-sectional area. (A) Satellite cell numbers 
were determined by the quantification of Pax7+ cells, and are expressed as a percentage 
of total myonuclei. (n= 8-9/treatment) No significant differences were observed between 
treatment groups. (B) Representative image of Pax7 (green) staining. Arrows indicate 
Pax7+DAPI+ satellite cells (x40; scale bar = 10µm). (C) Satellite cell proliferation was 
determined by the colocalization of Pax7+ and Ki67+ staining. No significant differences 
were observed between treatment groups (n=3/treatment). (D) Representative image of 
Pax7 (green)/ Ki67 (red) staining shown as individual channels and a merged image. 
Arrow indicates Pax7+Ki67+ colocalization (x40; scale bar = 10µm). (E) Body weights 
were recorded pre-, 1wk, 4wk post-transplantation. No significant differences were 
observed between treatment groups (n=24-26/treatment). (F-G) Muscle mass, reported 
as wet muscle weights, was not different between treatment groups 1wk or 4wks post-
transplantation (1wk, n=8-9/treatment; 4wk n=16-17/treatment). (H) Muscle growth, 
measured as increased myofiber cross-sectional area, did not different significantly 
between treatment groups at 1wk post-transplantation (n=8-9/treatment).  	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Figure 3.4. Neuromuscular adaptations lead to improvements in muscle function (A) 
Proper alignment of pre- and post-synaptic proteins were determined by the colocalization 
of α-bungarotoxin and synaptophysin. Significant differences were observed between 
treatment groups (p<0.05), with mMSCs+Strain displaying greater innervation percentages 
than mMSCs (p=0.135) and Saline (*p<0.01) groups (n=8-9/treatment). (B) Representative 
image of αBT (green)/Synap (red) staining. Solid arrows indicate properly aligned 
neuromuscular junctions, open arrow heads indicate dennervated junctions (x40; scale bar 
= 10µm). (C) Peak grip strengths were assessed pre-, 1wk, and 4wk post-transplantation. 
A main effect of treatment was observed (p<0.05), with significantly higher peak forces 
recorded in the mMSCs+Strain group as compared to Saline (*p<0.05) at the 4wk time 
point (n=11-12/treatment). (D) Maximal isometric forces were assessed 4 wk post 
transplantation. Using polynomial regression analysis, a significant treatment was observed 
with the force curve of mMSCs+Strain displaying a significant upward shift as compared to 
the Saline group (p=0.0225) (n=15-16/treatment). 	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Figure 3.5. Local vessel adaptations suggest a rightward shift in size distribution. 
(A) CD31+ vessels were quantified in multiple muscle tissue sections. No significant 
differences were observed between treatment groups in the density of vessels less 
than 5µm (n=8-9/treatment). (B) Similarly, no significant differences were observed in 
the density of vessels greater than 5µm (n=8-9/treatment). (C) Although no significant 
differences were observed in total numbers, the distribution of vessels greater than 
5µm display a rightward shift in the mMSCs+Strain group compared to both control 
groups. (D) Representative SPECT-CT image. (E) Hind limb perfusion was quantified 
by measuring maximal radioactivity captured in the SPECT images of each leg. 
Changes in perfusion are expressed as relative changes from baseline perfusion 
values. No significant differences were observed between treatment groups 
(n=5/treatment).  	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Figure 3.6. EGF released from mMSCs can get into circulation and affect 
neurogenesis. (A) Serum collected from young sedentary and young exercised 
animals was analyzed for the presence of EGF. With a significant effect of exercise 
(p<0.01), and an interaction of exercise and genotype (p=0.012), the α7Tg animals had 
significantly higher EGF levels post exercise than all other groups (*p<0.05) (n=6-
7/group). (B) Brains collected from these same animals were sectioned, and the 
hippocampus was stained for doublecourtin+ cells. (DCX; Representative image, scale 
bar= 200µm). (C) Quantitation of these data reveal a significant main effect of exercise 
(p<0.05) for total numbers of DCX+ cells. (D) DCX+ cell density (cell number normalized 
to hippocampus volume) did not reach significance (p=0.1077). (E) Because of the 
range of serum EGF levels assessed, EGF concentrations were correlated to total 
DCX+ cell number (Pearson’s r = 0.91; p=0.02). 	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Figure 3.7. Lentivirus-mediated shRNA knockdown of EGF in mMSCs. (A) Using a 
PLKO.1-puro vector, a short hairpin RNA construct designed to inhibit EGF production was 
inserted. mMSCs were transfected with shRNA_EGF or Scrambled RNA which served as a 
control. (B) Comparing RNA isolated from these cells, qRT-PCR confirmed that shRNA-
EGF expression levels were knocked down 60% compared to the Scrambled RNA controls 
(*p<0.05). (C) Serum collected from transfected cell transplant recipients further confirmed 
our model with shRNA_EGF cell transplant recipients displaying significantly lower levels of 
serum EGF than the Scrambled RNA control group (*p<0.05) (n=5/treatment).  	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Figure 3.8. Transplantation of mechanically strained cells leads to enhanced 
neurogenesis. (A) Representative image of the hippocampus stained for doublecortin 
(DCX) from a 24mo old animal (scale bar = 200µm). (B) Quantitation of total numbers 
of DCX+ cells within the granular layer of the dentate gyrus. Post hoc analysis revealed 
significantly higher numbers of DCX+ cells in the animals receiving mechanically 
strained cells (#p<0.05 shEGF_RNA vs. mMSCs, Scrambled RNA control vs. mMSCs; 
mMSCs+Strain vs. mMSCs p=0.066; shEGF and Scrambled vs. Saline p=0.054 and 
p=0.073, respectively) (C) When normalized to hippocampus volume, similar 
differences were observed (*p<0.05 shEGF_RNA vs. mMSCs, Scrambled RNA control 
vs. mMSCs; mMSCs+Strain vs. mMSCs p=0.09; shEGF and Scrambled vs. Saline 
p=0.116 and p=0.056, respectively) (n=5-11/treatment).  	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Figure 3.9. Enhanced neurogenesis results in hippocampus dependent cognitive 
gains. (A) Daily activity was monitored over the course of 4 days using TopScan video 
tracking software. No significant differences were observed between treatment group 
(n=11/treatment for all testing). (B) Using rotarod and (C) contextual fear conditioning 
tests hippocampus independent behaviors were tested. No significant differences 
between treatment groups were observed in these behaviors. (D) Through water maze 
based testing, the % time spent in target quadrant test showed near significant 
improvements in spatial learning (p=0.07), with a similar trend in the probe test (E). 
Both of these tasks are hippocampus dependent.	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CHAPTER 4 
α7 INTEGRIN, A POTENTIAL THERAPEUTIC TARGET IN THE PRESERVATION OF 
SKELETAL MUSCLE REPAIR OVER THE LIFESPAN 
 
4.1 Abstract 
 The natural process of aging can result in the loss of muscle mass as a result of 
both enhanced degradation, as well as loss of regeneration and growth of tissue.  The 
purpose of this study was to evaluate α7 integrin protein expression in mouse skeletal 
muscle over the lifespan and assess whether overexpression of the α7 integrin in 
muscle throughout the lifespan could effectively prevent damage and stimulate stem 
cells following injury provided by an acute bout of exercise.  Skeletal muscle tissue was 
collected from wild type (WT) and α7Tg animals at 6, 16, and 24 months of age. A 5 
week old cohort was added to evaluate α7 integrin protein expression.  Expression was 
significantly reduced at 6 mo compared to 5 wk in both WT and α7Tg muscle.  In 
agreement with previous observations, the α7 integrin protected against damage 
associated with exercise at 6 mo and trends were noted at 16 and 24 mo. Mesenchymal 
stem cell (MSC) number was enhanced at 24 hours post-exercise in α7Tg muscle, 
whereas no change was observed in WT. Although future studies are necessary to 
better understand the improved capacity for healing and maintenance of tissue mass 
with repeated exposure to injury, this study provides an initial evaluation of the effect of 
age on α7 integrin expression and the potential of this protein to act as a therapeutic 
target for the prevention of age-related disability. 
 
 
 
 
 
 
 
 
 
Keywords: α7 integrin, skeletal muscle, aging, mesenchymal stem cell 
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4.2 Introduction 
Integrins are transmembrane adhesion proteins comprised of noncovalently 
bound heterodimeric α- and β- subunits (39). Integrins link the cell to the surrounding 
extracellular matrix (ECM), while also converting mechanical stimuli into chemical 
information that can be interpreted by the cell (9). The α7β1 integrin is is highly 
expressed in skeletal muscle, localized to the sarcolemma at Z bands as well as within 
neuromuscular and myotendinous junctions (3, 29).  
Transgenic overexpression of the α7 integrin in mouse muscle (MCK:α7BX2; α7Tg) 
results in reduction in sarcolemmal damage and macrophage infiltration following 
eccentric exercise (9, 10, 33). Additionally, our lab has established that overexpression 
of the α7BX2 integrin  in mouse muscle can increase satellite cell number and new fiber 
synthesis following eccentric exercise, as well as enhance hypertrophic signaling, 
myofibrillar content, myofiber growth, and  maximal isometric force following single or 
multiple bouts of eccentric exercise (13, 19). The specific cellular mechanisms 
responsible for these adaptations, however, are not completely understood. 
Multipotent mesenchymal stem cells (MSCs) reside within the vascular niche of 
various tissues and function to promote tissue repair through the release of cytokines 
and paracrine factors, such as IGF-1, HGF, IL-6, leptin and EGF, which stimulate 
tissue-resident progenitor cells (2, 4, 7, 8, 11, 12, 14, 15, 15, 34). In skeletal muscle, 
MSCs primarily activate endogenous satellite cells to allow for repair of tissue following 
injury (4, 5, 12, 15). Our lab has recently established that muscle-derived Sca-1+CD45- 
MSCs (mMSCs) accumulate in skeletal muscle in a manner dependent on the presence 
of the α7 integrin and contribute to repair post-exercise (18, 40).  
Sarcopenia is the degenerative loss of muscle mass and function associated with 
age that affects a significant percentage of community-dwelling older adults (25, 27).  
While the precise etiology responsible for sarcopenia is not known, loss of muscle 
structure and function are the end result of processes that accelerate muscle catabolism 
or slow protein synthesis.  Several factors have been associated with a decrease in the 
size and number of muscle fibers, particularly fast-twitch, type II fibers, including: 1) 
increased protein catabolism (lysosomal, calcium-dependent, caspase-dependent, 
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ubiquitin proteasome-dependent), 2) increased oxidative stress, 3) inflammation, and 4) 
lack of regeneration (32).  
Due to the complexity of sarcopenia, current treatments are limited in their 
effectiveness, and the use of a multisystemic treatment is desirable (22).  Based on our 
previously published results, the α7 integrin is a logical therapeutic target for the 
treatment of sarcopenia. The purpose of this study was to 1) evaluate α7 integrin protein 
expression in mouse skeletal muscle over the lifespan and 2) assess whether 
overexpression of the α7 integrin in muscle throughout the lifespan could effectively 
prevent damage and stimulate stem cells following mild injury provided by an acute bout 
of exercise. Such enhanced protection and repair from minor injury associated with daily 
contractile activity would provide potential for preservation of maintenance of skeletal 
muscle mass and function throughout the lifespan. 
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4.3 Methods 
Animals. Transgenic mice overexpressing the α7BX2 integrin in skeletal muscle 
(SJL/C57BL6: MCK-α7BX2) were produced at the University of Illinois Transgenic Animal 
Facility as described (9, 12). Wild type littermates were also bred in house, and were 
used as controls. Protocols for animal use were approved by the Institutional Animal 
Care and Use Committee (IACUC) of the University of Illinois at Urbana-Champaign. All 
mice were housed in a temperature-controlled specific pathogen-free animal room 
maintained on a 12:12 light-dark cycle at the animal facility at the Beckman Institute. 
Three cohorts of animals were aged to 6, 16 and 24 months of age.  A young 5 week 
old control group was also used for some measures. At birth, each mouse was 
randomly assigned to one of these cohorts, with a goal of 7 animals in each condition 
per time point. Any animals found dead were eliminated from the study and recorded as 
subject attrition. Attrition rates from each cohort were documented and are reflected in a 
survival curve in the results section. Animals in the aged cohorts were fed a Pico diet 
and had access to water ad libitum. Animals used in the 5 week old control group were 
fed standard laboratory chow and had access to water ad libitum. The body weights 
were monitored weekly.  
 
Acute Bout of Eccentric Exercise. All animals either remained in a sedentary state or 
completed a single bout of eccentric exercise. The exercise protocol consisted of one 
downhill running bout (-20°, 30 minutes). The animals begin running at a speed of 
10m/min with the speed increasing 1m/min every minute. The speed was held constant 
at the maximum rate at which the animal was able to maintain running speed, with a 
maximum of 17 m/min. Following this exercise bout, animals were returned to their 
cages and undisturbed for the remainder of the study. 24 hours following this acute 
bout, all animals were euthanized and tissues were collected.  
 
FACS Quantification of mMSCs. Prior to stem cell isolation, 24 month old α7Tg mice 
were subjected to a single bout of eccentric exercise as described above. For both 
sedentary and exercised animals, gastrocnemius-soleus complexes were excised and 
Sca-1+CD45- cells were isolated. The muscle complexes were weighed prior to 
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digestion, and used to normalize total number of Sca-1+CD45- cells collected for each 
sample. Briefly, after mechanical and enzymatic digestion of the dissected muscle 
tissue, filtered samples were incubated on ice with anti-mouse CD16/CD32 (1 µg/106 
cells) (eBioscience, San Diego, CA) for 10 min in order to block non-specific Fc-
mediated interactions. Following the block, cells were stained in a cocktail of 
monoclonal anti-mouse antibodies Sca-1-PE (600 ng/106 cells) and CD45-APC (300 
ng/106 cells) (eBioscience, San Diego, CA) diluted in 2% Fetal Bovine Serum (FBS) in 
Phosphate Buffered Saline (PBS). Fluorescence activated cell sorting (FACS) was 
performed using an iCyt Reflection System (Champaign, IL), located at Carle Hospital 
(Urbana, IL). Negative and single-stained controls were used to establish gates. Sca-
1+CD45- cells were collected in 2% FBS and pelleted at 450 RCFs for 5 minutes.  The 
cells were then flash frozen for later analysis. 
 
Tissue Collection and Preservation. At the appropriate time points (6, 16 and 24 
months), gastrocnemius/soleus muscle complexes were collected from CO2 
asphyxiated animals. The muscles of one leg were weighed and immediately flash 
frozen in liquid nitrogen to be used for protein extraction and analysis. The muscles 
from the other leg were frozen in pre-cooled isopentane to be used for histological 
assessments. Blood was collected from the inferior vena cava post-mortem from a 
subset of animals. Following collection, blood samples were centrifuged at 15,000 RPM 
for 10 minutes and the serum was collected, flash frozen in liquid nitrogen, and stored at 
-80°C for future analysis.  
 
Protein Extraction and Western Blot Analysis. Frozen gastrocnemius-soleus complexes 
were ground manually with a mortar and pestle. The powdered tissue was homogenized 
in buffer containing 20mM HEPES (pH = 7.4), 2 mM EGTA, 50mM β-glycerophosphate, 
1mM dithiothreitol, 1mM Na3Vo4, 1% Triton X-100, and 10% glycerol, supplemented 
with 10 µM leupeptin, 3 mM benzamidine, 5 µM pepstatin A, 1 mM phenylmethylsulfonyl 
fluoride, and 10 µg/ml aprotinin. This was rotated for 1 hour at 4°C, then centrifuged at 
4°C for 15 minutes at 14,000 g and the supernatant was removed. The protein 
concentration was determined with a Bradford protein assay (Bio-Rad, Hercules, CA) 
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using BSA for the standard curve. 
 Equal amounts of protein (20µg) were separated by SDS-PAGE at 100V for 90 
minutes using 3.5% stacking and 8% resolving acrylamide gels. Non-reducing 
conditions were used. The sample was transferred to nitrocellulose membranes at 100V 
for 30 minutes on ice. Ponceau S staining was used to verify proper transfer. The 
membranes were blocked in 5% non-fat milk overnight at 4°C. The α7 integrin was 
detected by incubating membranes in purified α7 CDB347 polyclonal rabbit anti-rat 
antibodies (1:1000) for 1 hour (produced in house, 39). Following a series of washes, 
horseradish peroxidase-conjugated anti-rabbit secondary antibodies (1:10000) (Jackson 
ImmunoResearch Laboratories, West Grove, PA) were applied for 1 hour. Bands were 
detected using SuperSignal West Dura Extended Duration Substrate (Thermo Scientific, 
Rockford, IL) and a Bio-Rad ChemiDoc XRS system (Bio-Rad, Hercules, CA). 
Quantification was completed with Quantity One software (Bio-Rad), and was 
normalized to an unchanged Ponceau S band in all samples. 
  
Histology. Muscle complexes were divided at the midline along the axial plane, and 
embedded in OCT (Tissue-Tek; Fischer Scientific). Three transverse cryosections per 
sample (8-10µm non-serial sections, each separated by a minimum of 40 µm) were cut 
for each histological assessment using a CM3050S cryostat (Lecia, Wezlar, Germany). 
Sections were placed on microscope slides (Superfrost; Fischer Scientific, Hanover 
Park, IL) and stored at -80°C before staining. 
 
Immunohistochemistry. For all antibody based stains, the frozen tissue sections (8µm) 
were fixed in ice-cold acetone for 10 min and blocked with PBS containing 5% bovine 
serum albumin (BSA) followed by 70 µg/ml AffiniPure anti-mouse fab fragments diluted 
in 5% BSA (Jackson ImmunoResearch Laboratories, West Grove, PA) for 20 and 30 
minutes, respectively. 
 To assess α7B integrin expression and mMSC localization, tissue sections were co-
stained with rabbit polyclonal α7B (CD347, 1:500) and rat monoclonal Sca-1 antibodies 
(Ly-6A/E, 1:100) (BD Biosciences, Santa Cruz, CA). Both primary antibodies were 
diluted to their appropriate concentrations in 1% BSA, and were independently applied 
 95 
to the tissue sections for 1 hour at room temperature with a series of washes in between 
incubations. Tetramethyl rhodamine isothiocyanate (TRITC)-labeled anti-rabbit (1:250) 
and fluorescein isothiocyanate (FITC)-labeled anti-rat (1:100) secondary antibodies 
(Jackson ImmunoResearch Laboratories, West Grove, PA) were used to detect the α7B 
and Sca-1 antibodies, respectively. A 4,6-diamidino-2-phenylindole (DAPI) stain was 
added prior to the last wash (1:20,000) (Sigma Aldridge, St. Louis, MO) to allow for 
identification of nuclei. 
 To assess skeletal muscle damage, tissue sections were incubated with FITC-
conjugated anti-mouse IgG antibodies (FI2000, 1:100) (Vector Laboratories, 
Burlingame, CA).  The antibodies were diluted to their appropriate concentration in 1% 
BSA and were applied to the tissue sections at 4°C overnight. FITC-conjugation was 
used to detect IgG in the tissue.  A DAPI stain was added to prior to the last wash for 
identification of nuclei. 
 
Sirius Red Staining. To assess the accumulation of collagen in muscle tissue, frozen 
sections were stained with Picro-Sirius Red dye.  Briefly, the tissue sections (10µm) 
were fixed in Bouin’s solution (Fisher Scientific, Pittsburgh, PA) for 30 minutes. The 
sections, after being washed in running distilled water, were incubated for 20 minutes in 
Fast Blue Solution containing 0.1% Fast Blue RR Salt (F0500, Sigma Aldrich, St. Louis, 
MO), 7mM magnesium sulfate and 60mM magnesium borate (Fisher Scientific, 
Pittsburgh, PA) in order to prevent the uptake of the Sirius Red dye into the myofibers. 
The tissue sections were then incubated for 20 minutes in 0.1% Picro-Sirius Red dye 
containing Sirius Red F3B powder in picric acid (Polysciences, Warrington, PA). 
Following this incubation, the sections were washed for 10 seconds in acidified distilled 
water, then quickly dehydrated in a series of 90%, 95% and 100% ethanol, and briefly 
submerged in xylene.   
 
Image Capture and Analysis. All stained tissues were visualized with the use of a 
NanoZoomer digital slide scanner (Hamamatsu Corporation, Bridgewater, NJ) using the 
40X objective setting. In some instances, individual images for publication were 
captured on an upright inverted fluorescent microscope (Zeiss, Thornwood, NY), 
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excitation source (X-Cite 120, EXFO, Ontario, Canada) with the appropriate filter sets. 
Images were captured with a Ziess AxioCam digital camera and Axiovision software 
(Zeiss, Thornwood, NY).  
 For evaluation of IgG+ muscle fibers, entire sections were analyzed at 40X 
magnification using NDP.view2 viewing software (Hamamatsu Corporation, 
Bridgewater, NJ). A range of 1-3 sections per animal was analyzed depending on the 
quality of the section itself and/or the specificity of the stain. Images were acquired in 
separate color channels using the appropriate filter sets then analyzed as a merged 
image. The number of total IgG+ fibers was normalized to the total area of the tissue 
sections assessed using Adobe Photoshop (CS5 Extended). 
 For evaluation of Sirius Red stained tissue sections, images were captured in 
bright-field at 40X magnification using NDP.view2 viewing software. A range of 1-3 
sections per animal was analyzed depending on the quality of the section itself and/or 
the specificity of the stain. The total amount of collagen present in entire muscle 
sections was assessed and normalized to the total area of the tissue to obtain the 
percentage of collagen present using Cell Profiler software (Broad Institute, Cambridge, 
MA) (38).  
 
Grip Strength. Grip strength measurements for all four limbs were tested at the 6, 10, 16 
and 24 month time points prior to the acute exercise bout using an electronic Grip 
Strength Meter (Columbus Instruments, Columbus, OH). Any animal living at each of 
the time points was tested, regardless of its assigned cohort. All mice were acclimated 
to the procedure for three days prior to data collection. Briefly, mice were passed over a 
metal mesh grid connected to a force transducer and were given the opportunity to grab 
the grid with all fours limbs. The mice were then pulled away from the force transducer, 
and parallel to the grid at a constant rate until volitional release of the grid. The peak 
force in grams was recorded over the course of three independent trials. All 
measurements were performed by the same examiner who was blinded to the cohort 
and genotype of the animal. 
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Statistical Analysis. All data were averaged and presented as means + standard error 
and were analyzed by using SPSS (20.0, Chicago, IL) or Statistical Analyzing Software 
(9.2, Cary, NC). Differences were considered significant at p<0.05. For body weight 
data, polynomial regression was used to compare weights between genotypes with age. 
The muscle weight data were log transformed in order to improve the homogeneity of 
variance. The transformed data were then analyzed by two-way analysis of variance 
(ANOVA) with genotype, age and the interaction of genotype and age as factors. For 
the α7B protein expression analysis, the data were log transformed to improve the 
homogeneity of variance. A three-way ANOVA was run with age, genotype and exercise 
as factors. With no significant main effect of exercise, the exercise and sedentary 
groups were collapsed and a two-way ANOVA was run with age, genotype and the 
interaction of age and genotype as factors. IgG data were analyzed by three-way 
ANOVA with age, genotype, exercise and the interaction of genotype and exercise as 
factors. Because the interaction between genotype and exercise was close to reaching 
significance, this interaction was further investigated through two-way ANOVA in each 
age cohort, with genotype, exercise and the interaction of genotype and exercise as 
factors. Sirius Red data were squared to improve the homogeneity of variance. These 
data were analyzed by two-way ANOVA with age and genotype as factors. Grip 
strength data were assessed by polynomial regression comparing peak muscle force by 
age and genotype. Two-way ANOVA of the mMSC data showed close to significant 
effects of genotype and exercise. Because of the attrition rates and resultant low 
sample size, one-way ANOVA was used to analyze these data. Kaplan-Meier survival 
curve data were analyzed by a Chi2 Log Rank test. Tukey’s post hoc analyses were 
used to compare the means between groups.     
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4.4 Results 
α7B Protein Expression Declines Over the Lifespan 
In order to verify the model of α7 overexpression throughout the lifespan, α7B 
protein was quantified through western blotting (Figure 4.1A). With no effect of exercise 
observed (F1,77=0.224, p=0.623), the decision was made to analyze these data 
independent of this factor. Analyzing these collapsed data, the between animal 
expression of α7 varied significantly with main effects of age (F3,77=40.404, p<0.001) 
and genotype (F1,77=117.111, p<0.001). There was also a significant interaction 
between age and genotype (F3,77=11.805, p<0.001) observed. In the WT animals, the 
expression of α7B protein decreased significantly from the 5 week old cohort to each of 
the aged cohorts (p<0.01). In the α7Tg animals, although there was an effect of age on 
overexpression, α7B protein expression in each of the aged cohorts was never different 
than 5 week old WT protein expression (p>0.05). 
 
Muscle Damage is Higher Post-Exercise in Aged Skeletal Muscle, but is Protected with 
α7 Integrin Overexpression 
Muscle damage was evaluated by the assessment of IgG+ myofibers in multiple 
tissue sections (Figure 4.1B). Although not statistically significant (F1,57=1.643, 
p=0.109), the interaction between genotype and exercise warranted further 
investigation, so each cohort was analyzed individually. In the 6 month cohort, there 
was a significant main effect of exercise (F1,21=18.224, p<0.001) and a significant 
interaction of genotype and exercise (F1,21=7.789, p=0.012). Within this cohort, there 
was a significant increase in IgG density from the WT sedentary animals to the WT 
exercised animals (p=0.001).  In contrast, the 6 month α7Tg animals did not exhibit an 
increase in IgG density post-exercise (p>0.05), and had significantly lower IgG density 
than the WT exercised animals (p=0.022). Although the 16 and 24 month cohorts did 
not reach statistical significance, they followed similar trends as the 6 month cohort 
(Figure 4.1C). 
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mMSC Exercise Response is Preserved in α7Tg Animals 
One-way analysis of variance (ANOVA) showed significant differences in post-
exercise mMSC response between the groups (F3,11=4.06, p=0.0362) (Figure 4.2A).  
There was a significant difference in mMSC number when comparing the WT and α7Tg 
sedentary animals to α7Tg exercised animals (p=0.0108 and p=0.0136, respectively). 
There was also a trend for an increase in mMSC number from WT exercise to Tg 
exercised (p=0.0614). 
Collagen accumulation within the muscle tissue was also assessed via Sirius 
Red staining (Figure 4.3). This analysis was used as a marker of fibrosis. There was a 
significant main effect of age (F2,51=27.019, p<0.001), but no significant effect of 
genotype (F1,51=0.941, p=0.337). In both WT and α7Tg animals, there was a significant 
increase in the percentage of collagen from the 6 month to the 16 month cohort 
(p=0.004 and p=0.005, respectively). 
 
Muscle Mass is Preserved in α7Tg Animals 
For each of the aged cohorts, body weight was compared between groups. 
There was a significant effect of age (F1,68=85.42, p<0.001) and no effect of genotype 
(p>0.05), with both groups gaining weight with increasing age (Figure 4.4A). There was 
no significant interaction between age and genotype. 
Muscle mass was assessed after euthanization at the 6, 16 and 24 month time 
points, and is expressed as wet weights (Figure 4.4B). While there were no significant 
main effects of age or genotype, a significant interaction between age and genotype 
(F2,64=5.235, p=0.008) was observed. At 6 and 16 months, there were no significant 
differences in muscle mass (p>0.05), however the muscle mass in the 24 month α7Tg 
animals was significantly higher than the 24 month WT animals (p=0.045). 
Muscle function was assessed via limb grip strength measured in grams, and is 
reported as peak force (Figure 4.4C). Peak forces declined with increasing age in all 
animals, with effects of age (F1,41=9.42, p=0.0038) and of genotype (F1,58=2.08, 
p=0.1549), and only age reaching statistical significance. There was no significant 
interaction between age and genotype. 
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α7 Transgenic Animals Have Lower Attrition Rates 
Attrition rates were assessed as both WT and α7Tg were found dead before 
reaching the age of the cohorts they were assigned, preventing us from collecting 
tissues from these animals. These rates are documented in a Kaplan-Meier survival 
curve (Figure 4.5). While the survival rates were not significantly different (p=0.241), of 
the 17 animals found dead, 11 were WT and 6 were α7Tg animals. This correlates to a 
25% loss of WT animals and 15% loss of α7Tg animals due to unexpected death.   
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4.5 Discussion 
Previous studies have demonstrated the importance of the α7 integrin in 
protection from damage and the enhancement of regeneration in skeletal muscle (4, 5, 
9, 10, 12, 15, 33). Although accumulation of damage is increased and capacity for 
repair is decreased with age, it is unknown if these events are correlated to a decline in 
the presence and function of the α7 integrin (26, 36). The purpose of this study was to 
examine the extent to which age can alter α7 integrin protein expression in skeletal 
muscle and to assess whether overexpression of the α7 integrin in muscle throughout 
the lifespan could effectively prevent damage and stimulate resident stem cells following 
mild injury provided by an acute bout of exercise.   
To evaluate the effect of age on α7 integrin expression and to confirm our 
transgenic model, α7 integrin protein was quantitated and compared between 4 age 
groups. While expression in both genotypes was significanlty affected by age (Figure 
4.1A), transgenic expression in the aged cohorts never fell below WT expression levels 
in 5 week old animals. These data confirmed our hypothesis that the α7 integrin protein 
declines with age and may be an underlying mechanism in the age-related 
accumulation of skeletal muscle damage.  
By definition, sarcopenia has a significant effect on skeletal muscle mass (6, 24, 
21). Accounting for over 40-45% of body weight, muscle mass has a large impact on the 
overall health of an individual (16). When not properly maintained, decreases in lean 
mass are associated with increased risk of disability (37) and comorbidities such as type 
II diabetes and cardiovascular disease (20, 23, 35). A significant finding in this study 
was that muscle mass at the 24 month time point in the α7Tg animals was significantly 
higher than in the WT animals, suggesting overall maintenance of muscle in the α7Tg 
animals (Figure 4.4A). An unexpected finding was that neither genotype lost muscle 
mass over time. One explanation could be the tendency of the aged animals to become 
increasingly overweight with time, resulting in intramuscular fat deposition. 
A hallmark of aged skeletal muscle is the accumulation of damage with a 
concomitant increase in fibrosis (33). Given the role for the α7 integrin in protection from 
sarcolemmal damage, we chose to first assess damage by evaluating the density of 
IgG+ myofibers within WT and α7Tg skeletal muscle. In the 6 month cohort, damage 
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increased significantly in WT muscle in response to exercise. In contrast, damage was 
not present in α7Tg muscle post-exercise. Although the 16 and 24 month cohorts also 
did not reach statistical significance, all three cohorts followed similar trends (Figure 
4.1C). We speculate that due to natural attrition and increased variance with age, we 
did not have the statistical power to detect differences between groups within the 16 
and 24 month cohorts. Despite the lack of statistical significance, these data further 
confirm the potential of the α7 integrin to prevent damage in skeletal muscle following 
physiological injury created by eccentric or lengthening contractions.  
Our lab has demonstrated that Sca-1+CD45- MSCs are increased in skeletal 
muscle (mMSCs) following an acute bout of eccentric exercise (40). Although we don’t 
fully understand the mechanisms which underlie the accumulation of mMSCs post-
exercise, mMSC number and mMSC response to exercise appear to be α7 integrin 
dependent as they are minimally present in α7 knockout mice in the sedentary state and 
increased in α7Tg mice in the sedentary state and post exercise (40). This is the first 
study to assess whether a post-exercise mMSC response is affected by age. Using a 
FACS quantitation method, we found that, in the 24 month old cohort, the mMSC 
number in the α7Tg exercised animals was significantly higher than in the WT and α7Tg 
sedentary animals. There was also a trend for an increase in mMSC number from WT 
exercise to α7Tg exercised animals (Figure 4.2B). These data suggest that 
maintenance of the α7 integrin has the ability to preserve an important regeneration 
response in skeletal muscle. 
The accumulation of collagen and fat in skeletal muscle can negatively impact 
mMSC number and function.  Therefore, we assessed collagen content in WT and α7Tg 
muscle in the sedentary state at all ages. There was a steady increase in the 
percentage of collagen over time in both groups (Figure 4.3A). Although there was no 
difference in the percentage of collagen between genotypes, this assessment does not 
provide any information regarding the quality and type of collagen present. These 
assessments will be important as we begin to understand the precise factors (stiffness, 
collagen types) that regulate mMSC quantity and function  (30). 
In the current study, muscle mass was largely maintained, while muscle function 
decreased in WT mice with age (Figure 4.4C). While an improvement in muscle weight 
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was observed in α7Tg mice at 24 months, grip strength continued to decline in a manner 
similar to WT. These results were not entirely unexpected. Our previously published 
data suggest that overexpression of the α7 integrin by itself cannot significantly increase 
strength in young mice, but rather it can prevent loss of function as a result of exercise-
induced injury (32).  Therefore, it would be of interest to evaluate muscle weight and 
function in aged WT and α7Tg mice following inclusion of eccentric contractions on a 
regular basis to mimic the natural and active human lifestyle.  We predict that 
preservation of the α7 integrin would counter increased susceptibility to damage and 
lack of repair that is intrinsic to aged skeletal muscle. 
Because of the comorbidities associated with sarcopenia, survival rates, as a 
crude measure of overall health, were compared between genotypes (20, 23, 35). The 
survival rates between the WT and α7Tg animals were not significantly different, 
however, of the 17 animals found dead, 11 were WT and 6 were α7Tg, correlating to a 
25% loss of WT animals and a 15% loss of α7Tg animals (Figure 4.5). Although a large 
number of animals were included in this study, statistical differences in survival curves 
often require much larger sample sizes. For this reason, we do not downplay the 
implications that these data may have for the role of the α7 integrin and maintenance of 
muscle mass on overall health. 
 In conclusion, this study provides an initial evaluation of the effect of age on α7 
integrin expression and the potential of this protein as a therapeutic target. In the α7Tg 
model, overexpression of α7 protein over the lifespan never fell below the level of α7 
expression in 5 week old WT animals. Overexpression of the α7 integrin was able to 
increase muscle mass, prevent the accumulation of damage and preserve post-exercise 
mMSC response. Future studies will be necessary to better understand the 
mechanisms of improved capacity for healing and maintenance of tissue mass with 
repeated exposure to injury. 
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4.6 Figures and Figure Legends 
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Figure 4.1. α7B Protein Expression Over Time. (A) α7B protein expression was quantified, 
with a representative immunoblot of the 120 kD band shown. Fold changes comparing WT 
and α7Tg in each cohort are presented. All fold changes are presented relative to the 5 week 
WT group. In WT animals, the α7B protein expression decreased significantly from the 5 week 
old cohort to each of the aged cohorts (#p<0.01). There is a significant difference in α7B 
protein expression in the WT and α7Tg at the 5 week and 6 month time points (*p<0.001). In 
the 16 and 24 month α7Tg animals, the α7B protein expression is no different than 5 week old 
WT protein expression (p>0.05) (n=7-12/group). (B) Representative image of IgG stained 
skeletal muscle, with the arrow indicating damaged myofibers. FITC (green) = IgG and DAPI 
(blue) = myofiber nuclei (x20; scale bar = 20µm). (C) Quantitation of IgG+ myofibers per mm2 
of skeletal muscle tissue are presented for both sedentary and exercised conditions by 
genotype for each of the aged cohorts. In the 6 month cohort, there was a significant 
increase in IgG density from WT sedentary to WT exercised animals (*p=0.001). There was 
no significant increase in IgG density between α7Tg sedentary and exercised conditions 
(p>0.05), and a significantly lower density from WT exercised to α7Tg exercised groups 
(#p=0.022) (n=3-7/group). 	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Figure 4.2. mMSC Exercise Response. (A) In the 24 month cohort, the mMSC number, 
normalized to wet muscle weight, was quantified in both WT and exercised conditions by 
genotype. There was a significant increase in the mMSC number in the α7Tg exercised 
animals compared to sedentary WT and α7Tg animals (*p=0.0108 and *p=0.0136, 
respectively). There was also a trend for an increase in mMSC number from exercised WT 
to α7Tg animals (p=0.0614) (n=3-5/group). (B) Representative images are shown of α7/Sca-
1 stained skeletal muscle for WT and α7Tg animals in both sedentary and exercised 
conditions for each age cohort. FITC (green) = Sca-1, TRITC (red) = α7, and DAPI (blue) = 
myofiber nuclei (x40; scale bar = 40µm).    	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Figure 4.3. Collagen Density. (A) Collagen accumulation in skeletal muscle tissue 
was quantified and is shown by genotype in each age cohort. There is a significant 
effect of age (p<0.001), with a significant increase in the percentage of collagen in the 
WT and α7Tg animals from the 6 to 16 month cohorts (*p=0.004 and *p=0.005, 
respectively) (n=3-6/group). (B) Representative images of collagen (red) in exercised 
WT and α7Tg skeletal muscle in each aged cohorts stained with Sirius red dye (x20; 
scale bar = 20µm). 	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Figure 4.4. Body Weight, Muscle Mass, and Function. (A) Body weight increased 
significantly with age (p<0.001) and there was no effect of genotype on body weights. (B) 
Muscle mass as wet weights at 6, 16 and 24 months are represented. In the 24 month 
cohort, the muscle mass in the α7Tg animals was significantly higher than the WT 
animals (*p=0.045) (n=7-24/group/time point). (C) Peak force, measured by grip strength, 
is presented by genotype at 6, 10, 16 and 24 months. There were effects of age 
(p=0.0038) and genotype (p=0.1549), with only age reaching statistical significance (n=6-
14/group/time point). 	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Figure 4.5. Kaplan-Meier Survival Curve. Attrition rates were assessed as animals were 
found dead and are presented in the survival curve shown. The survival rates are not 
statistically significant (p=0.241). Of the 17 animals found dead, 11 were WT (25% loss) and 
6 were α7Tg (15% loss) (n=84 animals).  	  
 112 
4.7 Acknowledgements 
We would like to thank Emily Kolyvas, Nicole Zachweija, Kelly Ryan, Eli Khazoum, and 
Sabina Cashin for their assistance in collection and data analysis. We would also like to 
thank Justin Rhodes for all of his assistance with the statistical analyses of these data. 
This work was supported by a grant from the Ellison Medical Foundation (to MDB). HDH 
was supported by a National Science Foundation Integrative Graduate Education and 
Research Traineeship (IGERT) in Cellular and Molecular Mechanics and 
BioNanotechnology (CMMB). None of the authors declared any conflict of interest. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 113 
4.8 References 
1. Administration on Aging, US Department of Health and Human Services. 2011. “A 
Profile of Older Americans: 2010.” 1–17.  
 
2. Amado, L.C., Saliaris, A.P., Schuleri, K.H., St. John, M., Xie, J.S., Cattaneo, S., 
Durand. D.J., Fitton, T., Kuang, J.Q., Stewart, G., Lehrke, S., Baumgartner, W.W., 
Martin, B.J., Heldman, A.W., and Hare, J.M. 2005. “Cardiac repair with 
intramyocardial injection of allogeneic mesenchymal stem cells after myocardial 
infarction.” Proc Natl Acad Sci, 102: 11474-11479. 
3. Ambrosio, F., Ferrari, R.J., Distefano, G., Plassmeyer, J.M., Carvell, G.E., Deasy, 
B.M., Boninger, M.L., Fitzgerald, G.K., and Huard, J. 2010. “The synergistic effect of 
treadmill running on stem-cell transplantation to heal injured skeletal muscle.” Tissue 
Eng Part A, 16: 839-849. 
4. Armstrong, R.B. 1990. “Initial events in exercise-induced muscular injury.” Med Sci 
Sports Exerc, 22: 429-435. 
5. Aumailley, M., Bruckner-Tuderman, L., Carter, W.G., Deutzmann, R., Edgar, D., 
Ekblom, P., Engel, J., Engvall, E., Hohenester, E., Jones, J.C., Kleinman, H.K., 
Marinkovich, M.P., Martin, G.R., Mayer, U., Meneguzzi, G., Miner, J.H., Miyazaki, K., 
Patarroyo, M., Paulsson, M., Quaranta, V., Sanes, J.R., Sasaki, T., Sekiguchi, K., 
Sorokin, L.M., Talts, J.F., Tryggvason, K., Uitto, J., Virtanen, I., von der Mark, K., 
Wewer, U.M., Yamada, Y., and Yurchenco, P.D. 2005. “A simplified laminin 
nomenclature.” Matrix Biol, 24: 326-332. 
6. Baumgartner, R.N., Waters, D.L., Gallagher, D., Morley, J.E., and Garry, P.J. 
1999. “Predictors of Skeletal Muscle Mass in Elderly Men and Women.” Mechanisms of 
Ageing and Development, 107: 123–36. 
7. Berthier. C., and Blaineau, S. 1997. “Supramolecular organization of the 
subsarcolemmal cytoskeleton of adult skeletal muscle fibers. A review.” Biol Cell, 89: 
413-434. 
8. Birbrair, A., Zhang, T., Wang, Z.M., Messi, M..L, Enikolopov, G.N., Mintz, A., and 
Delbono, O. 2013. “Skeletal muscle pericyte subtypes differ in their differentiation 
potential.” Stem Cell Res, 10: 67-84. 
9. Boppart, M.D., Burkin, D.J., and Kaufman, S.J. 2006. “α7β1-integrin regulates 
mechanotransduction and prevents skeletal muscle injury.” Am J Physiol Cell Physiol, 
290: C1660-C1665. 
10. Boppart, M.D., Volker, S.E., Alexander, N., Burkin, D.J., and Kaufman, S.J. 
2008. “Exercise promotes α7 integrin gene transcription and protection of skeletal 
muscle. Am J Physiol Regul Integr Comp Physiol, 295: R1623–R1630. 
 114 
11. Boppart, M.D., Burkin, D.J., and Kaufman, S.J. 2011. “Activation of AKT signaling 
promotes cell growth and survival in α7β1 integrin-mediated alleviation of muscular 
dystrophy.” Biochim Biophys Acta, 1812: 439-446. 
12. Burkin, D.J., Wallace, G.Q., Nicol, K.J., Kaufman, D.J., and Kaufman, S.J. 2001. 
“Enhanced expression of the α7β1 integrin reduces muscular dystrophy and restores 
viability in dystrophic mice.” J Cell Biol, 152: 1207-1218. 
13. Caplan, A.I., and Bruder, S.P. 2001. “Mesenchymal stem cells: building blocks for 
molecular medicine in the 21st century.” Trends Mol Med 7, 259-264. 
14. Caplan, A.I. 2009. “Why are MSCs therapeutic? New data: new insight.” J Pathol, 
217: 318 –324. 
15. Carlson, S., Trial, J., Soeller, C., and Entman, M.L. 2011. “Cardiac mesenchymal 
stem cells contribute to scar formation after myocardial infarction.” Cardiovasc Res, 91: 
99-107. 
16. Chakkalakal, J.V., Jones, K.M., Basson, M.A., and Brack, A.S. 2012. “The Aged 
Niche Disrupts Muscle Stem Cell Quiescence.” Nature, 490(7420): 355–60. 
17. Crawley, S., Farrell, E.M., Wang, W., Gu, M., Huang, H.Y., Huynh, V., Hodges, 
B.L., Cooper, D.N., and Kaufman, S.J. 1997. “The α7β1 integrin mediates adhesion 
and migration of skeletal myoblasts on laminin.” Exp Cell Res, 235: 274–286. 
18. Dellavalle, A., Sampaolesi, M., Tonlorenzi, R., Tagliafico, E., Sacchetti, B., 
Perani, L., Innocenzi, A., Galvez, B.G., Messina, G., Morosetti, R., Li, S., Belicchi, 
M., Peretti, G., Chamberlain, J.S., Wright, W.E., Torrente, Y., Ferrari, S., Bianco, P., 
and Cossu, G. 2007. “Pericytes of human skeletal muscle are myogenic precursors 
distinct from satellite cells.” Nat Cell Biol, 9: 255-267. 
19. Dev, K.K., Nishimune, A., Henley, J.M., and Nakanishi, S. 1999. “The protein 
kinase C α binding protein PICK1 interacts with short but not long form alternative splice 
variants of AMPA receptor subunits.” Neuropharmacology, 38: 635-644. 
20. Dutta, C. 1997. “Significance of Sarcopenia in the Elderly.” Journal of Nutrition, 127: 
992S–993S. 
21. Faulkner, J.A., Larkin, L.M., Claflin, D.R., and Brooks, S.V. 2007. “Age-Related 
Changes in the Structure and Function of Skeletal Muscles.” Clinical and Experimental 
Pharmacology and Physiology, 34(11): 1091–96. 
22. Fielding, R.A., Vellas, B., Evans, W.J., Bhasin, S., Morley, J.E., Newman, A.B., 
van Kan, G.A., Andrieu, S., Bauer, J., Breuille, D., Cederholm, T., Chandler, J., De 
Meynard, C., Donini, L., Harris, T., Kannt, A., Guibert, F.K., Onder, G., 
Papanicolaou, D., Rolland, Y., Rooks, D., Sieber, C., Souhami, E., Verlaan, S., and 
Zamboni, M. 2011. “Sarcopenia: an Undiagnosed Condition in Older Adults. Current 
Consensus Definition: Prevalence, Etiology, and Consequences. International Working 
 115 
Group on Sarcopenia.” Journal of the American Medical Directors Association, 12(4): 
249–56. 
23. Guralnik, J.M., Ferrucci, L., Pieper, C.F., Leveille, S.G., Markides, K.S., Ostir, 
G.V., Studenski, S., Berkman, L.F., and Wallace, R.B. 2000. “Lower Extremity 
Function and Subsequent Disability: Consistency Across Studies, Predictive Models, 
and Value of Gait Speed Alone Compared with the Short Physical Performance Battery.” 
Journal of Gerontology: Medical Sciences, 55A(4): M221–31. 
24. Hameed, M., Harridge, S.D.R., and Goldspink, G. 2002. “Sarcopenia and 
Hypertrophy: a Role for Insulin- Like Growth Factor-1 in Aged Muscle?.” Exerc Sport Sci 
Rev, 30(1): 15–19. 
25. Hansen-Smith, F., Egginton, S., Zhou, A.L., and Hudlicka, O. 2001. “Growth of 
arterioles precedes that of capillaries in stretch-induced angiogenesis in skeletal 
muscle.” Microvasc Res, 62: 1–14. 
26. Hermann, M., and Berger, P. 2001. “Hormonal Changes in Aging Men: a 
Therapeutic Indication?.” Experimental Gerontology, 36: 1075–82. 
27. Janssen, I. 2006. “Influence of Sarcopenia on the Development of Physical 
Disability: the Cardiovascular Health Study.” Journal of the American Geriatrics Society, 
54(1): 56–62. 
28. Janssen, I., Shepard, D.S., Katzmarzyk, P.T., and Roubenoff, R. 2004. “The 
Healthcare Costs of Sarcopenia in the United States.” Journal of the American 
Geriatrics Society, 52(1): 80–85. 
29. Kaariainen, M., Nissinen, L., Kaufman, S., Sonnenberg, A., Jarvinen, M., Heino, 
J., and Kalimo, H. 2002. “Expression of α7β1 integrin splicing variants during skeletal 
muscle regeneration.” Am J Pathol, 161: 1023-1031. 
30. Kume, S., Kato, S., Yamagishi, S.I., Inagaki, Y., Ueda, S., Arima, N., Okawa, t., 
Kojiro, M., and Nagata, K. 2005. “Advanced Glycation End-Products Attenuate Human 
Mesenchymal Stem Cells and Prevent Cognate Differentiation Into Adipose Tissue, 
Cartilage, and Bone.” Journal of Bone and Mineral Research, 20(9), 1647–1658. 
 
31. Lenk, K., Schuler, G., and Adams, V.. 2010. “Skeletal muscle wasting in cachexia 
and sarcopenia: molecular pathophysioogy and impact of exercise training.” Journal of 
Cachexia, Sarcopenia and Muscle, 1(1): 9-21. 
  
32. Lueders, T.N., Zou, K., Huntsman, H.D., Meador, B.M., Mahmassani. Z., Abel, 
M., Valero, M.C., Huey, K.A., and Boppart, M.D. 2011. “The α7β1-integrin accelerates 
fiber hypertrophy and myogenesis following a single bout of eccentric exercise.” Am J 
Physiol Cell Physiol, 301: C938–C946. 
 116 
33. Mann, C.J., Perdiguero, E., Kharraz, Y., Aguilar, S., Pessina, P., Serrano, A.L., 
and Muñoz-Cánoves, P. 2011. “Aberrant repair and fibrosis development in skeletal 
muscle.” Skeletal Muscle, 1, 1–20. 
  
34. Meirelles L.D.S, Fontes, A.M., Covas, D.T., and Caplan, A.I. 2009. “Mechanisms 
involved in the therapeutic properties of mesenchymal stem cells.” Cyto- kine Growth 
Factor Rev, 20: 419–427. 
35. Metter, E.J., Talbot, L.A., Schrager, M., and Conwit, R. 2002. “Skeletal Muscle 
Strength as a Predictor of All-Cause Mortality in Healthy Men.” Journal of Gerontology: 
Biological Sciences, 57A(10): B359–65. 
36. Payne, A.M., Zheng, Z., Messi, M.L., Milligan, C.E., González, E., and Delbono, 
O. 2006. “Motor Neuron Targeting of IGF-1 Prevents Specific Force Decline in Ageing 
Mouse Muscle.” The Journal of Physiology, 570(2): 283–94. 
37. Rao, S.S. 2005. “Prevention of Falls in Older Patients.” American Family Physician, 
72: 81–88. 
38. Sant'Anna, L.B., Sant'Anna, N., and Parolini, O. 2011. “Application of computer 
assisted image analysis for identifying and quantifying liver fibrosis in an experimental 
model.” Journal of Computational Interdisciplinary Sciences, 2(2), 139–148. 
 
39. Song, W.K., Wang, W., Sato, H., Bielser, D.A., and Kaufman, S.J. 1993. 
“Expression of α7 integrin cytoplasmic domains during skeletal muscle development: 
alternate forms, conformational change, and homologies with serine/threonine kinases 
and tyrosine phosphatases.” J Cell Sci, 106 ( Pt 4): 1139-1152. 
40. Valero, M.C., Huntsman, H.D., Liu, J., Zou, K., and Boppart, M.D. 2012. 
“Eccentric exercise facilitates mesenchymal stem cell appearance in skeletal muscle.” 
PLoS One, 7: e29760. 
 
 
 
 
 
 
 
 
 
 
 117 
CHAPTER 5 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
 The primary aim of this study was to develop a preconditioning method to increase 
the survival of effectiveness of mMSC transplantation, and to evaluate the ability for 
preconditioned mMSCs to positively impact muscle function with age. mMSCs 
preconditioned with mechanical strain prior to transplantation did not influence satellite 
cell number or increase muscle growth, yet increased preservation of the 
neuromuscular junction and improved muscle strength in aged mice. Secondly, we 
wanted to evaluate whether the growth and neurotrophic factors released from mMSCs 
could systemically influence adaptations in distant tissues. Interestingly, transplantation 
of preconditioned mMSCs significantly increased neurogenesis in the hippocampus and 
positively influenced cognitive function  
 The presence of the α7 integrin in muscle can enhance mMSC content.  Therefore, 
overexpression of the α7 integrin in muscle provides an alternative strategy to stem cell-
based therapeutics.  In the second study, α7 integrin protein expression declined in wild 
type mice with age.   Transgenic expression of the α7 integrin in muscle resulted in 
protection from exercise-induced damage at 6 months of age and increased muscle 
mass and the MSC response to exercise at 24 months.  Interestingly, the α7Tg mice 
also had lower attrition rates, suggesting improved overall health. Although future 
studies will be necessary to better understand the mechanisms that underlie these 
adaptations, this study provides an initial evaluation of the effect of age on α7 integrin 
expression and the potential of the α7 integrin as a therapeutic target. 
 In conclusion, the results from these studies demonstrate that both mMSCs and 
the α7 integrin can drive important local adaptations, and prevent some of the 
maladaptive responses associate with age such as decreased blood supply, 
denervation, and the accumulation of damage. Therefore, we believe that our results 
provide sufficient evidence for developing mMSC and α7 integrin-based therapies to 
improve muscle health and prevent the loss of function associated with aging and 
neuromuscular disorders. 
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Future studies are necessary to investigate the following questions: 
 
1. In the current study the effect of preconditioned mMSC transplantation was often a 
minor increase in adaptation or function. To what extent would increased mMSC 
number, or number of transplantations enhance these responses? 
 
2. Of primary interest in these studies was adaptation of traditional markers of muscle 
growth such as increased muscle mass, increased myofiber cross-sectional area, and 
satellite cell number and proliferation. Unfortunately, only one or two timepoints were 
able to be assessed in the current study.   Do these factors increase with mMSC 
transplantation and/or overexpression of the α7 integrin at a more optimal timepoint? 
 
3. Preconditioning methods enhanced the survival and function of transplanted 
mMSCs? How long do these beneficial effects last in vivo?  Is there a method that can 
be developed to allow for continuous stimulation of transplanted mMSCS? 
 
4. What are the mechanisms that underlie positive adaptations observed α7Tg mice? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
